Home
>
Warning: Undefined property: WP_Error::$name in /var/www/medicalconferences/wp-content/themes/writers-blogily-new/category.php on line 78
Deprecated: strtolower(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/medicalconferences/wp-content/themes/writers-blogily-new/category.php on line 78
Warning: Undefined property: WP_Error::$name in /var/www/medicalconferences/wp-content/themes/writers-blogily-new/category.php on line 84
> Disease Areas
Warning: Undefined property: WP_Error::$name in /var/www/medicalconferences/wp-content/themes/writers-blogily-new/category.php on line 78
Deprecated: strtolower(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/medicalconferences/wp-content/themes/writers-blogily-new/category.php on line 78
Warning: Undefined property: WP_Error::$name in /var/www/medicalconferences/wp-content/themes/writers-blogily-new/category.php on line 84
> Disease Areas
Disease Areas
Featured articles
Atypical and radiological-only presentations often meet 2024 MS criteria
Meet the Trialist: Dr Jiwon Oh
CONTENTS
Online First
Management of atopic dermatitis in children in 2025
Pulsed field non-inferior to cryoballoon ablation in symptomatic paroxysmal AF
FAIR-HF2: the value of intravenous iron in patients with HF plus iron deficiency
Restricting fluid in HF may not be good practice after all
REVERSE-IT: Bentracimab restores platelet function in ticagrelor-users
Lorundrostat represents novel class of BP-lowering drugs
Acute Coronary Syndrome
REVERSE-IT: Bentracimab restores platelet function in ticagrelor-users
ZODIAC: Can we improve lipid-lowering strategies in ACS?
IVUS-guided PCI beats angiography in patients with acute coronary syndrome
ACS: Necessary DAPT after PCI may be shorter than currently advised
Immediate or staged revascularisation in STEMI plus multivessel disease?
Lp(a) and cardiovascular events: which test is the best?
Guidelines for Acute Coronary Syndrome
Can aspirin be omitted after PCI in patients with high bleeding risk?
DAPT or clopidogrel monotherapy after stenting in high-risk East-Asian patients?
Immediate complete revascularisation non-inferior to staged complete revascularisation
Half-dose tenecteplase safe and effective for STEMI without timely PCI
Combination of filgrastim and dutogliptin appears safe in STEMI
ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA
COMPLETE revascularisation improves angina-related QoL
Low-resource countries benefit from global STEMI initiative
Ticagrelor cessation: early CABG non-inferior to delayed surgery
REVERSE-IT: Interim analysis shows promising effect of bentracimab on ticagrelor reversal
PIONEER III trial: Drug-eluting stents comparable
2020 Non-ST-Segment Elevation Acute Coronary Syndromes Guidelines
Trimetazidine after successful PCI not associated with fewer cardiac events
Increased mortality with colchicine in patients with ACS
Fewer adverse events with ticagrelor monotherapy after 3 months DAPT
Finding the sweet spot of anticoagulation in AF patients with ACS
Apixaban in AF patients with recent ACS/PCI: Drop aspirin after 30 days
Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI
Phase 3 BETonMACE trial did not meet its primary endpoint
Less bleeding and fewer hospitalisations with antithrombotic regimen with apixaban without aspirin
Alopecia
Bempikibart shows its potential for hair regrowth in alopecia areata
Ivarmacitinib stimulates hair regrowth in severe alopecia areata
Baricitinib regrows hair in adolescents with alopecia areata
Deuruxolitinib significantly improves hair satisfaction in AA
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
What’s new in clinical dermatology?
Baricitinib maintains regrowth of hair, eyebrows, and eyelashes over 3 years
Botanical drug solution leads to sustained hair regrowth in paediatric alopecia
SGLT2 inhibition: A possible mode-of-action for inflammatory skin diseases?
Ritlecitinib also effective in patients with total hair loss
JAK3/TEC inhibition achieves clinically meaningful responses in AA
Alopecia areata: remarkable regrowth rates with deuruxolitinib
Botanical drug solution improves hair regrowth in children and adolescents with AA
Patients with AA report high long-term regrowth rates with baricitinib
Can ritlecitinib deliver long-term efficacy in alopecia areata?
TikTok videos on hair disorders lack reliability
JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
The rise of JAK inhibitors for alopecia areata
Long-term improvement in alopecia areata with ritlecitinib therapy
Topical gel plus finasteride beneficial for patients with androgenetic alopecia
Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata
No adverse pregnancy outcomes in patients exposed to baricitinib
Alopecia areata: light at the end of the tunnel
Alopecia areata pathogenesis: known genetic background, unknown environmental triggers
Alopecia areata: 1-year baricitinib treatment increases success
JAK1/2: A promising novel treatment target in alopecia areata
Alopecia areata: encouraging response rates with JAK3/TEC inhibition
Allergies: an underrated factor in alopecia pathogenesis
Botulinum toxin A: a contradictory role in hair loss
Platelet-rich plasma in androgenetic alopecia – hype or hope?
JAK inhibitors in AA: re-establishing the immune privilege of hair follicles
Spironolactone safe for androgenetic alopecia in cancer survivors
Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata
Novel treatment options in alopecia areata and vitiligo
JAK1/2 inhibitor effective in alopecia areata
JAK inhibitors: a pathogenesis-directed therapy for alopecia areata
Hair Loss: No Reason for Therapeutic Nihilism
A glimpse into the future
New agents and combination therapy
Alzheimer's & Dementia
Vagal nerve stimulation for the reduction of cognitive impairment in Alzheimer’s disease
Under investigation: Opioid use and the risk for dementia
Intensive BP intervention reduces risk of dementia
Nightmares during childhood linked to cognitive decline later in life
Towards cell biology of Alzheimer’s disease
Contribution of genomics and genetics to personalised medicine
How big data can boost care for neurodegenerative disorders
Alzheimer’s disease and dementia: the road towards proactive and preventive care
Lecanemab may slow decline of cognition and function in Alzheimer’s Disease
Donanemab shows rapid and deep plaque clearance in early Alzheimer’s Disease
Key correlates of incident dementia identified in the MESA study
Diabetes not related to abnormal biomarkers of Alzheimer’s disease
Large impact of COVID-19 on dementia diagnosis and care
Risk factors for dementia in RA patients discovered
Biologic treatment decreases dementia risk in senior IBD patients
Cardiorespiratory fitness protects against dementia
Safety and effects of bosutinib in Lewy body dementia
Computational model of Alzheimer’s links symptoms, brain anatomy, mental processing
Biogen publishes Alzheimer’s drug data in lesser-known journal
Tau buildup in brain tied to psychosis, more rapid decline in Alzheimer’s disease
Alzheimer’s-like changes seen in COVID-19 patients’ brains
Reduced risk of Alzheimer’s disease in CHIP carriers
Post-traumatic amnesia, chronic vascular lesions risk factors for Alzheimer’s after TBI
Online self-test detects mild cognitive impairment shift to dementia sooner than MMSE
Researchers find ‘promising’ blood biomarkers for cognitive decline in dementia
MEF2 expression linked to cognitive resilience in Alzheimer’s disease
Tau replication in local brain regions, not spread between regions, drives Alzheimer’s pathology
Tau accumulation in brain likely best biomarker of short-term cognitive decline in Alzheimer’s
Study questions screening for subclinical thyroid dysfunction to prevent cognitive decline
Severe outcomes of COVID-19 in patients with dementia
Promising diagnostic accuracy of plasma GFAP
Sex modulates effect of cognitive reserve on subjective cognitive decline
Hypersensitivity to uncertainty in subjective cognitive decline
APOE-e4 allele tied to Alzheimer’s clinical and biomarker changes in Down syndrome
Calculator validated for home-based dementia risk screening
Statins not tied to incident dementia or cognitive decline in older adults
Motor change patterns may suggest preclinical Alzheimer’s disease
Obstructive sleep apnoea associated with lower cognition
NfL is a better marker for neurodegeneration than T-tau
Monoclonal antibody rapidly reduces brain amyloid
Pimavanserin does not worsen motor function in patients with neurodegenerative disease
Lipophilic statins may raise risk of conversion from MCI to dementia
Biological definition of Alzheimer’s disease not suitable for clinical diagnosis
Video exam may be effective alternative to in-person cognitive assessments
Dense-core amyloid plaques may be protective, not destructive, in Alzheimer’s disease
Whole-genome sequencing reveals rare variants tied to Alzheimer’s disease
More evidence that gum disease may play a role in Alzheimer’s disease
Retinal changes may signal pre-clinical Alzheimer’s disease neuropathology
Sargramostim shows promise in Alzheimer’s disease
Retinal damage may signal risk for stroke and dementia
Little consensus on referral to specialist palliative care for dementia patients
Link between cardiovascular-risk management and dementia protection remains elusive
Visual reads of PET scans can help predict near-term clinical progression of dementia
High risk of vascular dementia in patients with T2D
Study supports link between endosomal-traffic defect and Alzheimer’s
Neuroinflammation common in familial frontotemporal dementia
Predicting MCI and dementia by assessing worrying about memory
Genomics of vascular dementia and stroke
The PRISM project: focusing on biological parameters across neuropsychiatric disorders
![Table. ATN-profiles and corresponding biomarker categories [3].](https://conferences.medicom-publishers.com/wp-content/uploads/2020/09/Table.-ATN-profiles-and-corresponding.png)
Non-Alzheimer’s disease pathophysiology in the elderly
Novel genetic association with resistance to ERC tau deposition
Diastolic dysfunction novel risk factor for cognitive impairment
A necessary shift of focus to the earlier stages of Alzheimer’s
Antipsychotics increase mortality regardless of comorbidity
Amyloid PET in cognitively impaired patients
Tight blood pressure control lowers risk of mild cognitive impairment
Two experimental antibodies reduce amyloid levels
How to implement brain-healthy behaviour in clinical practice
Ankylosing Spondylitis
ICI therapy does not increase mortality risk in patients with pre-existing autoimmune disease
Registry participation can enhance quality of rheumatology care
Dual IL-17A/F blocker significantly reduces spinal radiographic progression in radiographic axSpA
AxSpA: Higher comorbidity burden worsens radiographic progression
Low IL-18: a hidden culprit of long COVID in patients with autoimmune disease
AxSpA: Adalimumab biosimilar equally effective as IL-17 inhibitor in hindering radiographic progression
Ankylosing spondylitis: Combining biologics with NSAID does not imply reduced radiographic progression
Alarmingly low activity in patients with non-inflammatory and inflammatory rheumatic disease
How to treat enthesitis in 2022
Treat-to-target dose reduction effective in spondyloarthritis
A novel oral treatment possibility for non-radiographic axSpA on the horizon
SELECT-AXIS: 64-week results of upadacitinib in active ankylosing spondylitis
JAK inhibition as a treatment option for ankylosing spondylitis
Signs of benefit for T2T in axial spondyloarthritis
Artificial intelligence can help in the diagnosis of axSPA
Reduced maintenance dose of certolizumab pegol can be used in axSpA
Worse response axSpA patients to second TNFi versus first TNFi
AxSpA real-life remission rates higher on biologics
Certolizumab pegol reduces acute anterior uveitis in axial spondyloarthritis
TNF-α inhibitors improve bone mineral density in AS patients
Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib
JAK1 inhibition shows remarkable efficacy in AS
CARDAS study shows increased prevalence of cardiac valvular disorders in AS patients
Treat-to-target approach emerging in axial spondyloarthritis
NSAIDs consumption is linked to patient-assessed disease activity and decreases with use of TNF inhibitors
IBD risk of treatment with IL-17 antagonists
Clinical effect of vedolizumab on articular manifestations spondyloarthritis associated with IBD
Osteoporosis and vertebral fractures associated with disease activity/radiographic damage in axial spondyloarthritis
Synergistic effect NSAIDs plus TNFi in slowing radiographic progression in ankylosing spondylitis patients
Switching to biosimilar bDMARDs is safe and efficacious
Low bone mineral density is common in axial spondyloarthritis; more awareness required
Anxiety
Anxiety and depression: Lifestyle influential in MACE prevention
Worse self-management in patients with inflammatory arthritis in the presence of comorbid anxiety or depression
Comorbid anxiety and depression may benefit from psoriasis treatment with certolizumab
Vortioxetine effectively reduces symptoms of depression and anxiety
Cannabidiol for cannabis cessation shows positive results
Novel approaches to understanding the social brain
Anxiolytic activity of a novel orexin-1 receptor antagonist
ECNP 2021 Highlights Podcast
Possible aetiologies for COPD exacerbations – more evidence is needed
Baby’s heart rate shows stress if their mother is depressed or anxious
Possible causal link between eosinophilic inflammation and anxiety
Microbial composition and psychological wellbeing
Asthma & COPD
UCAP: Identify and treat undiagnosed COPD or asthma
Structural and functional lung improvement with dupilumab in asthma
sRAGE: A novel potential biomarker to assess the risk of acute respiratory events
Most severe asthma patients are candidates for biologic therapy on a global scale
Gabapentinoids increase risk of exacerbations in COPD
Future treatment of fatigue in COPD: 4 possible targets identified
Tapering from high-dose inhaled corticosteroids possible in most asthma patients treated with benralizumab
Tezepelumab therapy: hints toward a disease-modifying effect?
Digital inhaler programme improves asthma control also in the long term, but not long-term adherence
Wildfire smoke in New York: adapting to a new respiratory reality
Vitamin D for asthma protection: what is the optimal timing?
Practice-changing results for ensifentrine in COPD
Alvelestat for AATD meets primary endpoints in phase 2 trial
Fewer exacerbations with dupilumab in COPD with type 2 inflammation
Remarkable results for novel biologic therapy for asthma
Efficient detection of AECOPD with at-home vital signs monitoring
Success for fluticasone furoate plus vilanterol in uncontrolled asthma
Antibiotics cause increased risk of wheezing in severe RSV bronchiolitis
Tezepelumab in asthma: mucus plugging down, lung function up
Digital asthma intervention improves health and reduces costs
Digitally enhanced therapy lowers treatment burden and costs in severe asthma
Mepolizumab beneficial for patients with severe eosinophilic asthma
Icenticaftor achieves results on top of triple inhalation therapy in COPD
STARR2: A new approach for treating COPD exacerbations
COPD medication not effective in symptomatic smokers with preserved spirometry
Do digital tools improve physical activity in COPD?
Hyperpolarised gas MRI ready for clinical use
Physical activity improves asthma control
Tailored exercise needed for COPD patients
Asthma increases risks around delivery
PRO-ART study: unravelling the link between asthma and subfertility
Early-onset and uncontrolled asthma: strong association with recurrent pregnancy loss
Round-up of respiratory disease and reproduction topics
Severe asthma in the spotlights
Common comorbidities in severe asthma
Targeting treatable traits allows a personalised approach to management of (severe) asthma
Exercise-induced laryngeal obstruction (EILO) is often misdiagnosed
The ULANC Group: working together in CRSwNP/asthma
E-cigarettes impose detrimental effects on health
Effects of passive vaping in COPD patients
MANDALA and DENALI pattern success for albuterol-budesonide in asthma
ACOUSTICS data sounds good for adolescent asthma exacerbations
Type 2 asthma in children managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
High-intensity interval training slashes daily corticosteroids in asthma
Three’s a crowd for triple therapy in COPD
Higher 1-year COPD mortality after hospitalisation for White patients
Reducing dyspnoea in chronic lung disease through weight loss
CT-evident mucus plugs in COPD associated with death
Home-based rehabilitation improves COPD: a randomised study
No screening evidence for COPD
Telemedicine has mixed influence on costs of asthma care
Dupilumab cuts severe asthma exacerbations by 59% in children aged 6 to 11
Understudied low-lung-function state tied to increased risk of respiratory problems and death
Rhinovirus bronchiolitis increased risk of recurrent wheezing and asthma
Livestock farming affected the airway microbiome of COPD patients
Adherence to singing training similar to standard physical therapy in COPD patients
COPD symptoms and lung function related to sleep quality
Reduction of COPD severe acute exacerbations by candidate vaccine
The effect of the pandemic on the discharge diagnosis of older COPD patients
Lower influenza vaccination coverage in children with chronic conditions
Biomarkers do not discriminate severe from severe uncontrolled asthma
Increased blood neutrophiles in patients with obesity and asthma
Dynamics of environmental pollution during and after COVID-19 lockdown
Magnesium supplements improved lung function in asthma patients
Blood inflammatory phenotypes associated with clinical symptoms of asthma
Paradoxical bronchospasm may go unrecognized in patients with COPD or asthma
Circadian system implicated in asthma worsening at night
Restoring pulmonary endothelial cells reverses emphysema in mice
Vaping identified as risk factor for asthma
Obesity: A risk factor for new-onset asthma and worse asthma control
Metabolic dysfunction and lung disease: children are no small adults
Possible aetiologies for COPD exacerbations – more evidence is needed
Does COPD plus COVID-19 equal higher mortality?
Biomarkers for acute exacerbations in COPD are required
Severe exacerbations: A key driver of all-cause mortality in COPD patients
Men and women with COPD differ in many ways
Younger adults with COPD at higher health risk than previously thought
“As-needed” inhaled corticosteroid therapy for mild asthma – what is the evidence?
IL-4/13 blocker successful in treatment of paediatric moderate-to-severe asthma
Benralizumab lives up to its phase 3 results in real-world findings
Tezepelumab – good success rates in various types of severe asthma
Frequent snoring tied to increased asthma symptoms, health care use in kids
HRT tied to increased risk of severe asthma exacerbation
Dupilumab an option when other targeted agents fail in aspirin-exacerbated respiratory disease
Bronchial thermoplasty benefits for uncontrolled asthma sustained at 10 years
Benralizumab improves health-related quality of life in severe eosinophilic asthma
Disinfecting during pandemic puts asthmatics at risk
Children with exercise-induced respiratory symptoms may get conflicting diagnoses
Anti-IL-5 biologics effective for up to two years in severe asthma, but residual disease remains
Smartphone-based cough detection helpful in predicting asthma deterioration
The role of chronic symptoms as early biomarkers of COPD development
Urgent call for studies in COPD patients aged 40-60 years
Nasal high-flow therapy: a novel treatment option for hypercapnic COPD patients
Exacerbation history is a reliable predictor of future exacerbations
Singing training effective as physical rehabilitation in COPD
Mild asthma: A fundamental change in management
Dupilumab shows long-term efficacy in asthma patients
Severe asthma: Oral corticosteroids maintenance therapy associated with toxicity
First-in-class tyrosine kinase inhibitor shows promise in severe asthma
Predicting individual effectiveness of biologics in severe asthma
Current prediction tools underestimate exacerbation risk of severe COPD patients
IL-5 antagonist showed efficacy in chronic rhinosinusitis with nasal polyps
Treatment according to genotype: The future of asthma therapy?
Asthma rescue with budesonide-formoterol cuts short-term flare risk
For COPD with nocturnal hypoxemia, nighttime oxygen has no survival benefit
Limited evidence supports escalation of therapy for acute asthma exacerbations in kids
Smart shirt as a device to measure tidal volumes in real-life setting
COPD patients harbouring Pseudomonas Aeruginosa face high risk of hospitalisation
Exercise with virtual reality beneficial for COPD patients
One blood eosinophil count is sufficient to guide ICS therapy
Female COPD patients frequently suffer from anxiety and depression
COPD patients do not benefit from azithromycin therapy longer than a year
Pneumococcal vaccines: an effective way to reduce COPD hospitalisations
Dual bronchodilation improves ventilation dynamics in COPD patients
Holistic view on asthma
Dupilumab improves outcomes in patients with severe chronic rhinosinusitis with nasal polyps and comorbid asthma
Benralizumab does not ameliorate COPD exacerbations (GALATHEA/TERRANOVA trials)
Ensifentrine for COPD maintenance treatment
Treatable traits in chronic inflammatory airway disease: back to basics
Aclidinium bromide delays COPD exacerbation without increased MACE risk
[Long Read] Current Look on Asthma
Landmark triple therapy trials
Endoscopic treatment of asthma
ICS: to use or not to use?
MABA, and novel LAMA
Macrolide antibiotics and trial with azithromycin
Atopic Dermatitis
Flexing upadacitinib dose adjustment for AD and itch relief
ROCKET ignites interest in rocatinlimab
Management of atopic dermatitis in children in 2025
3-Year results highlight durable effects of IL-13 inhibitor in AD
IL-22RA1 inhibition shows potential in atopic dermatitis
Lifelong psychosocial burden linked to early-onset atopic dermatitis
Second-generation selective PDE4 inhibitor shows promise in AD
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
What’s new in clinical dermatology?
Children with atopic dermatitis may be smaller and heavier than healthy children
Amlitelimab leads to a high response 28 weeks after treatment discontinuation
Delgocitinib cream: A promising treatment option for chronic hand eczema
Tapinarof on course to become a new topical treatment in AD
Upadacitinib provides sustained skin clearance in adolescents and adults with AD
Sustained deep clinical and itch responses with novel IL-13 inhibitor
IL-13 inhibitor shows potential in atopic dermatitis
Encouraging results for amlitelimab in atopic dermatitis
Frequent co-existence of atrial fibrillation and obstructive sleep apnoea in stroke patients
As-needed ruxolitinib shows successful long-term symptom control in AD
Dupilumab: a viable option for atopic hand and foot eczema
Topical roflumilast beneficial in atopic dermatitis
IL-22 receptor blocker reduces itch and skin lesions in AD
Delgocitinib shows promise as topical therapy for chronic hand eczema
Eligibility and selection of JAK inhibitors for constitutional eczema
Baricitinib possible therapeutic option for children with AD
Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients
IL-13 inhibition with lebrikizumab shows high maintenance rates in AD
Does 8 weeks of emollients use prevent AD in high-risk infants?
Therapies for atopic dermatitis: still moving forward
Children with AD: high risk of bacterial infections in carriers of a filaggrin gene variant
No adverse pregnancy outcomes in patients exposed to baricitinib
AD treatment during the pandemic: dupilumab does not raise COVID-19 infection risk
Upadacitinib: Fast and more pronounced skin improvement in AD patients
JAK inhibitors in AD: Setting the efficacy bar even higher
Novel IL-4/IL-13 blocker shows high efficacy with only modest conjunctivitis signal
JAK inhibitors: A risk assessment
Monitoring is key during JAK inhibitor therapy
Dupilumab for atopic dermatitis linked with milder COVID-19 symptoms
Targeting OX40 in the treatment of atopic dermatitis meets expectations
Superior EASI scores after switch from dupilumab to upadacitinib
Long-term disease control in AD could be in reach with anti-OX40 antibody KHK4083
Abrocitinib demonstrates fast itch control and skin clearance in atopic dermatitis
AD patients with stable response fare well with a monthly dose of tralokinumab
Upadacitinib beats dupilumab in different body regions
Efficacious 2-year AD control with IL-13 inhibitor tralokinumab
Ruxolitinib cream: a safe treatment for elderly AD patients
Novel and upcoming targeted AD treatment
Opioid receptor agonist difelikefalin disappoints in AD
EADV 2021 Highlights Podcast
Potential first-in-class drug shows disease-modifying impact in atopic dermatitis
Do oral corticosteroids drive fracture risk in atopic eczema?
Severe atopic dermatitis tied to depressive symptoms, internalizing behaviors in children
Upadacitinib bests dupilumab for adults with moderate-severe atopic dermatitis
Comorbidity does not influence crisaborole efficacy in atopic dermatitis
Comorbidity is common in adult and paediatric atopic dermatitis patients
Significant improvements in the system armamentarium for AD treatment
No increased risk of infection with long-term dupilumab for atopic dermatitis
Topical pan-JAK inhibitor cream safe and efficacious in atopic dermatitis
Atopic dermatitis in children has a severe impact on their families
Meaningful amelioration of quality of life in paediatric AD patients on dupilumab
Etrasimod – a new mode of action for treatment of atopic dermatitis
Baricitinib shows long-term effectiveness against moderate to severe atopic dermatitis
Wildfire air pollution linked to jump in atopic dermatitis and itch dermatology visits
Pfizer’s atopic dermatitis drug bests dupilumab, but only at higher dose
Pediatric atopic dermatitis tied to school, work absenteeism
Severe atopic eczema tied to higher risk of premature death
Meaningful sleep improvement with IL-13 inhibition
Baricitinib in AD: Efficacy paired with consistent long-term results
Topical JAK inhibition: a novel treatment option for patients with mild-to-moderate AD
Oral JAK 1 inhibitor leads to fast itch relieve and remarkable skin clearance in AD
Effects IL-13 blocker improves with longer treatment duration
Baricitinib beneficial in head and neck AD
Good response and pruritus reduction in AD with novel selective JAK1 inhibitor
IL-13 blocker tralokinumab effective in AD
Tape stripping – a painless way to distinguish AD and psoriasis?
IL-4/IL-13 blocker dupilumab effective in children with severe AD
Better compliance in AD skin care with novel emollient stick
Small molecules: interesting novel treatment options in AD
IL-1⍺ blockade: a new treatment option in AD
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents
JAK inhibition plus TCS lead to high clearance rates in AD
How to manage conjunctivitis in AD patients treated with a biologic
Biologics: increasingly used in paediatric dermatology
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD
Green light for a second JAK inhibitor in AD
Comorbidities more common in chronic urticaria, psoriasis, and AD
Reduced sleep quality in dermatoses influenced by itch and pain
Anxiety and depression are common in families of AD infants
Statin use elevates risk of eczema and atopic dermatitis
Cutaneous adverse events due to EGFR inhibitors
Insights into pathogenesis of AD define novel therapeutic targets
Long awaited oral therapy for moderate-to-severe AD
Reduction in coronary artery disease in psoriasis patients treated with biologic therapies, possible implications for atopic dermatitis
Atopic dermatitis and psoriasis: on a spectrum?
Bermekimab – a future treatment for atopic dermatitis?
New and emerging atopic dermatitis therapies
Tralokinumab improves eczema and reduces staphylococcus aureus colonisation in AD
Can JAK inhibitors close the current therapeutic gap in AD?
Living in the golden age of psoriasis and atopic dermatitis therapies
Atrial Fibrillation
Pulsed field non-inferior to cryoballoon ablation in symptomatic paroxysmal AF
PROMPT-AF: Novel ablation strategy improves outcomes for persistent AF
ARREST-AF: The true impact of risk factor management on AF recurrence after ablation
OPTION: LAAC over OAC after ablation in patients with AF and increased stroke risk
Head-to-head: Cryoballoon vs radiofrequency ablation in persistent AF
Guidelines for the management of atrial fibrillation
EPIC-CAD: What is the best antithrombotic approach in high-risk AF plus stable CAD?
OCEANIC-AF: Asundexian inferior to apixaban for ischaemic stroke prevention in AF
MIRACLE-AF: Elegant solution to improve AF care in rural China
SUPPRESS-AF: What is the value of adding LVA ablation to PVI in AF?
STEEER-AF: Shockingly low adherence to ESC atrial fibrillation guidelines
SGLT2 inhibitors decrease atrial fibrillation risk in patients with HFrEF
Ablate-by-LAW: CT-determined left atrial wall thickness for ablation titration in atrial fibrillation
Personalised LAWT-guided ablation non-inferior to CLOSE protocol for paroxysmal atrial fibrillation
Style-AF: Improved outcomes with vascular closure versus figure-of-eight suture
ASTRO AF: No benefit of staged left atrial appendage isolation cryoballoon ablation over radiofrequency ablation
Pulsed-field ablation vs high-power short-duration radiofrequency in paroxysmal AF
MRI head-to-head comparison of lesion quality following various ablation techniques
“Single-shot” conformable catheter shows promising efficacy in paroxysmal atrial fibrillation
AF burden versus classical AF classification in predicting arrhythmia recurrence
ARTESiA: Stroke risk unaffected by subclinical atrial fibrillation duration
Ablation strategy and the number of repeat procedures not associated with atrial fibrillation recurrence
Factors associated with negative outcomes in post-operative atrial fibrillation
Smartphone rhythm monitoring optimises AF management following cardiac surgery
New atrial fibrillation associated with a high risk of major cardiovascular outcomes
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Liraglutide may improve post-ablation outcomes in obese patients with AF
Single or dual cardioversion in patients with obesity and AF?
NOAH-AFNET 6: Does the duration of AHRE influence response to edoxaban?
ARTESIA: How useful is anticoagulation in subclinical AF?
Catheter ablation saves lives in end-stage HF with AF
Minimising atrial pacing does not reduce the risk for AF in sinus node disease
Results of FRAIL-AF trial suggest increased bleeding risk with DOACs
Does colchicine prevent perioperative AF and MINS?
Pulsed-field ablation appears safe and effective for atrial fibrillation
Surgery saves lives in patients with oesophageal fistula
MANIFEST-PF: Good results for the pentaspline PFA catheter
POWER FAST III: High-power, short-duration radiofrequency ablation for AF
High-power, short-duration ablation linked to a higher stroke risk
Early or delayed ablation for AF?
CEASE-AF meets primary endpoint in persistent AF
Prolonged ECG monitoring detects relevant arrhythmias in HCM
Statins display benefits for AF patients in a large population-based study
ANTWERP score selects HF patients for AF ablation
First-line ablation limits progression to persistent AF
AF: Moderate alcohol intake possibly associated with a reduced mortality risk
Periodontitis: An independent risk factor for AF
Rheumatic heart disease-associated AF: standard-of-care holds ground
Smartphones for AF detection
PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation
Sex differences revealed in AF determinants and AF progression
Early rhythm-control therapy efficacious in men and women with AF
Progression in remote app-based monitoring of atrial fibrillation
First results of the POWER FAST III trial
Real-world safety results on pulsed-field ablation with pentaspline catheter
Low AF recurrence rates after PVI using pulsed-field ablation
Ultrasound-guided femoral venipuncture reduces complications in catheter ablation
Focus on the efficacy of cardiac resynchronisation therapy in HF plus concomitant AF
Insertable cardiac monitors effective for AF detection in cryptogenic stroke
Developments in imaging tools for AF
Large impact of remote screening tool on sleep apnoea diagnoses in AF
Impact of AF screening on stroke prevention influenced by systolic blood pressure
Inhaled flecainide promising for atrial fibrillation
NOAC could be better than warfarin in diabetes patients with atrial fibrillation
Apixaban plus P2Y12 inhibitor likely best for AF after ACS or PCI
New developments in remote diagnostics and monitoring of AF
Head-to-head: Efficacy of dabigatran versus warfarin on cognitive impairment
Posterior left pericardiotomy safe and effective in reducing atrial fibrillation
LAA ligation did not reduce recurrent atrial arrhythmias in persistent AF
Equal benefits of early rhythm control in AF subtypes
Atrial fibrillation symptoms less likely to be noticed by patients with diabetes
Women with breast cancer at increased risk for developing atrial fibrillation
Fitbit algorithm reliably detects atrial fibrillation
AI-enabled ECG algorithm predicts atrial fibrillation risk in migraine
Stroke risk rises transiently with AF episodes in patients with implanted cardiac devices
Healthy sleep patterns tied to healthier heart rhythms
Continuous monitoring detects atrial fibrillation up to 30 days after discharge
ESC 2021 Highlights Podcast
Drinking alcohol tied to increased atrial fibrillation risk hours later
Omecamtiv mecarbil might be less effective in patients with atrial fibrillation or flutter
Vericiguat effective irrespective of atrial fibrillation status
COVID-19 in AF patients with HF: no higher mortality but longer hospital stay
Psychoactive substances put young people at risk of cardiovascular disease
Can a glass of wine a day keep a-fib away?
Atrial fibrillation after SAVR or TAVR tied to poorer outcome
Apixaban has benefits over other DOACs in frail adults with atrial fibrillation
Athletes may have doubled A-fib risk compared to general public
Favourable outcomes with transcatheter atrial appendage occlusion
STRENGTH trial fails to demonstrate cardioprotective effect of omega-3 fatty acids
Ablation-based rhythm control as effective as rate control in AF and HF
Finerenone reduces the risk of AF onset in patients with CKD and diabetes
With hypertrophic cardiomyopathy, age and BMI among predictors of AFib events
Ablation bests drug therapy for minorities with afib in North America
ECG biomarker identifies AFib patients most likely to benefit from electrical stimulation
EHRA Practical Guide on cardiac imaging in electrophysiology
Early rhythm-control ablation: insight from the CHARISMA registry
Personalised pulmonary vein isolation procedure feasible and effective
Pulmonary vein isolation: cryoballoon non-inferior to radiofrequency ablation
Pulmonary vein isolation lesions plus personalised methods shows promising results
Predictors of young-onset atrial fibrillation
RACE 3 long-term results show fading benefit of targeted therapies in AF and HF
Deep dive into EAST-AFNET 4 results on early rhythm-control in atrial fibrillation
Cryo-FIRST study: improved AF and QoL outcomes with cryoballoon versus drug therapy
STROKESTOP: Benefits of systematic screening for atrial fibrillation
DOACs and bleeding: the role of antidotes
2021 EHRA practical guide: DOACs in pre-operative and bleeding patients
Accelerometer-derived physical activity tied to atrial fibrillation risk
Finerenone may delay onset of atrial fibrillation in at-risk patients
Afib patients benefit when left-atrial-appendage occlusion added to their heart surgery
Anticoagulation common near end of life in dementia patients with AFib
Pulsed field ablation effective against paroxysmal atrial fibrillation
Catheter ablation likely more effective than drugs for paroxysmal atrial fibrillation
Many patients on DOACs receive concurrent non-indicated aspirin tied to bleeding risk
DOACs safer, more effective than warfarin in valvular atrial fibrillation
Screening with wearable ECG increased AF detection 10-fold in hypertensive older adults
AF monitoring following cardiovascular surgery
Pre-diabetes tied to increased stroke risk with nonvalvular atrial fibrillation
Vitamin D or omega 3 fatty acids do not prevent AF
Active screening for AF improves clinical outcomes
AF screening in older adults at primary care visits
Unfavourable outcomes for COVID-19 patients with AF and atrial flutter
High blood pressure likely to be causally linked to atrial fibrillation
Left atrial appendage occlusion tied to less afib bleeding, mortality vs DOACs
Cryoablation Afib studies show better first-line outcomes than drug therapy
Rivaroxaban not inferior to warfarin for afib patients with artificial mitral valve
Direct oral anticoagulants may best vitamin K agonists for post-TAVR a-fib
Cryoballoon supplement to pulmonary-vein isolation curbs AF recurrence
2020 Atrial Fibrillation Guidelines
Reduced cardiovascular outcomes with early rhythm control
Drug initiation strategy not associated with increased use of oral anticoagulants
Digoxin improves symptoms in stable patients with permanent AF
Surgical bleeding risk most important determinant of bleeding outcomes
Similar bleeding rates in patients with VTE and AF treated with DOACs
Factor V Leiden mutation linked to atrial fibrillation
Finding the sweet spot of anticoagulation in AF patients with ACS
Apixaban in AF patients with recent ACS/PCI: Drop aspirin after 30 days
Infusion of ethanol in the vein of Marshall for persistent AF
Apple Heart Study: Not just for atrial fibrillation
Early apixaban safe as secondary prevention of stroke from AF
Lower rates stroke/SE with DOACs in frail non-valvular AF patients
Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry
Substantial impact of temporary interruptions of warfarin versus DOAC
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Less bleeding and fewer hospitalisations with antithrombotic regimen with apixaban without aspirin
Smartwatch can detect atrial fibrillation with high degree of accuracy
Bladder Cancer
Perioperative durvalumab combined with neoadjuvant chemotherapy improves survival in bladder cancer
Watchful waiting is non-inferior to BCG in patients with T0 after second transurethral resection
Immune-enhancing nutrition does not affect complication rate of radical cystectomy
Shorter hospital stay with robotic surgery versus open surgery in bladder cancer
Improved risk stratification for high-risk NMIBC
Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC
Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin
Better survival with neoadjuvant dose-dense MVAC regimen in MIBC
EAU TV: The best on bladder cancer and renal cell carcinoma
Best of EAU: Highlights on bladder cancer
ctDNA can guide adjuvant immunotherapy in muscle-invasive bladder cancer
Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma
Circulating tumour cells could aid in the decision to give neoadjuvant chemotherapy
Poorer outcomes in bladder cancer predicted by race/ethnicity and gender
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 3 results
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 2 results
Signature DNA alterations in subtypes of bladder cancer
ACE inhibitors associated with superior responses in bladder cancer
Better allocation of research dollars needed
Nadofaragene firadenovec effective in BCG-unresponsive papillary NMIBC
Enfortumab vedotin and pembrolizumab in advanced bladder cancer: initial results
Largest safety study of its kind with atezolizumab in metastatic bladder cancer
Bladder cancer risk and early detection
Consensus treatment pathway for patients with limited pelvic lymph node involvement in otherwise localised bladder cancer
FGFR3 gene mutation: Favourable prognostic impact in bladder cancer
Bladder cancer in young patients
Spanish study directly links surgical volume with mortality in bladder cancer patients undergoing cystectomy
Updated interim results of phase 2 trial of pembrolizumab for high-risk NMIBC unresponsive to BCG
Robot-assisted radical cystectomy or open radical cystectomy?
Breast Cancer
Margetuximab does not improve pCR rate in HER2-positive early breast cancer
Obesity is associated with worse prognosis in early-stage breast cancer
T-DXd outperforms T-DM1 regardless of baseline genomic alterations in HER2-positive metastatic breast cancer
Immediate surgery can offer long-term benefits for elderly patients with early-stage breast cancer
Long-term benefit of olaparib seen in high-risk early BRCA1/2-mutated breast cancer
Encouraging results of neoadjuvant SHR-A1811 in the treatment of HER2-positive breast cancer
Active monitoring is a viable option for patients with low-risk DCIS
Additional CDK4/6 inhibition in HER2-positive patients achieves clinically meaningful outcomes
NATALEE: Success with adjuvant ribociclib leads to FDA approval in early breast cancer
Inavolisib: The first FDA-approved treatment for use in a triple combination for metastatic breast cancer
Imlunestrant monotherapy improves PFS in ESR1-mutated patients, not in the overall population
Neoadjuvant niraparib plus dostarlimab shows pCR benefit in BRCA-mutated, ER-positive/HER2-negative breast cancer
Neoadjuvant HER3-DXd achieves pCR and ORR results similar to multi-agent chemotherapy
SONIA: Potential to defer CDK4/6 inhibitor treatment without impacting HRQoL
Improved TTF and PFS seen with palbociclib plus ET in real-world PADMA study
KEYNOTE-522 finds prognostic value of TMB and gene profiles in TNBC
The ZEST trial sheds light on the use of ctDNA to predict breast cancer recurrence
No added EFS benefit with neoadjuvant atezolizumab in TNBC
No OS benefit at 10 years with post-mastectomy RT in intermediate-risk breast cancer
Single-modality radiotherapy may better preserve HRQoL than ET in elderly patients
Tamoxifen reduces ipsilateral breast recurrence in “good risk” DCIS patients without RT
Meet the Trialist: Prof. Hope Rugo on the P-VERIFY results
Trastuzumab deruxtecan also effective in patients with brain metastases
High pCR rates with dual neoadjuvant immunotherapy in TIL-high TNBC
Local HER2 IHC0 is often HER2-low or -ultralow
First-line capivasertib improves PFS but not OS in metastatic TNBC
Breastfeeding does not increase the risk of breast cancer recurrence
More highlights in Breast Cancer
Benefit of abemaciclib plus fulvestrant after progression on a CDK4/6 inhibitor
ctDNA is prognostic of worse outcomes for CDK4/6 therapy
Adjuvant avelumab significantly improves survival in early TNBC
High pCR rate after neoadjuvant Dato-DXd plus durvalumab therapy
Meet the Trialist: Prof. Giuseppe Curigliano on DESTINY-Breast06
No cardioprotective effect of ACE inhibitors in patients with cancer
Bilateral mastectomy and breast-conserving surgery have equal impact on breast cancer-specific mortality in pathogenic BRCA1 carriers
Highest benefit of neoadjuvant nivolumab in breast tumours with high PD-L1 expression and/or low ER expression
(More) axillary surgery does not influence long-term recurrence
Neoadjuvant chemotherapy may help patients skip regional nodal irradiation
No radiotherapy after breast-conserving surgery is safe in selected younger patients
Tucatinib improves PFS in metastatic, HER2-positive breast cancer
OS benefit of adjuvant T-DM1 in early breast cancer with residual disease after neoadjuvant therapy
Atezolizumab improves pCR in HER2-positive early breast cancer
Adjuvant ribociclib improves IDFS in early breast cancer
Addition of inavolisib to palbociclib and fulvestrant reduces risk of progression
Endocrine therapy response provides information on need of adjuvant chemotherapy
monarchE: No predictive biomarkers revealed with molecular profiling
No predictive biomarkers found in PALLAS
Olaparib maintenance has favourable safety profile in TNBC
High pCR with neoadjuvant nivolumab/chemotherapy in stage I–II TNBC
Exercise programme improves quality of life for patients with metastatic breast cancer
Fast menstrual resumption after interruption of endocrine therapy
Pregnancy is not contraindicated in pathogenic BRCA carriers
Benefit of pembrolizumab in TNBC remains after 5 years of follow-up
Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer
Long-term air pollution exposure at both residential and workplace locations increases breast cancer risk
Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy
Know Your Lemons for breast cancer detection
SONIA: No survival benefit with first-line versus second-line CDK4/6 inhibition in metastatic breast cancer
Adjuvant ribociclib improves invasive DFS in early breast cancer
Gene expression profiles predict benefit of neoadjuvant immune checkpoint therapy in triple-negative breast cancer
Racial disparity in the tumour microenvironment
Chemo-endocrine therapy worse for cognition than endocrine therapy alone
Resistance to CDK4/6 inhibitors is likely due to expansion of pre-existing resistant clones
Baseline CTC count can guide first-line treatment in HR-positive/HER-negative metastatic breast cancer
Germline pathogenic variants for breast cancer also increase contralateral breast cancer risk
Low-dose tamoxifen still prevents recurrence from non-invasive breast cancer
Endocrine interruption to pursue pregnancy does not impact short-term disease in breast cancer
ZNF689 deficiency promotes intratumour heterogeneity and resistance to immune checkpoint blockade in TNBC
Oestradiol represses anti-tumoural immune response to promote progression of brain metastases
Benefit of adjuvant abemaciclib continues to deepen at longer follow-up
First-line ribociclib plus endocrine therapy outperforms combination chemotherapy
Treatment options beyond CDK4/6 inhibition
Trastuzumab deruxtecan effective in both second-line and neoadjuvant setting
Anti-PD-1/anti-LAG-3 combination highly effective in HER2-negative breast cancer
MammaPrint test predictive for benefit of extended endocrine therapy
Tumour infiltrating lymphocytes identify patients with immunogenic triple-negative breast cancer
OS benefit of abemaciclib in HR-positive/HER2-negative advanced breast cancer not (yet) statistically significant
OS benefit of sacituzumab govitecan in pre-treated HR-positive/HER2-negative metastatic breast cancer
Bacterial decolonisation effective against radiation dermatitis
Sacituzumab govitecan meets primary endpoint
Shaky OS results of palbociclib in ER-positive/HER2-negative breast cancer
Practice-changing results of T-DXd in HER2-low breast cancer
SET2,3 to inform on chemotherapy decisions in ER-positive breast cancer
Metastasis-directed therapy fails in oligometastatic breast cancer
Analysis by residual cancer burden further clarifies effect of pembrolizumab
Contribution of metastatic therapies on mortality reduction in breast cancer
Radiotherapy may be omitted in breast cancer patients
Promising data for ribociclib after progression on ET plus CDK4/6 inhibitors in HR-positive/HER2-negative metastatic breast cancer
7-gene biosignature: Benefits of endocrine therapy and radiotherapy in breast cancer risk groups
Diagnostic mammogram accuracy varies across racial/ethnic groups
Lumpectomy on par with mastectomy for some young women
Positive lymph nodes not a reliable indicator for chemo in some women with breast cancer
Trastuzumab deruxtecan slashes disease progression, death by 72% in HER-2+ breast cancer
Mammograms may provide clues to heart-disease risk in older women
Breast, cervical screening suboptimal in transgender individuals
Adding ribociclib to letrozole boosts survival in some with advanced breast cancer
DNA damage repair may be key to higher breast cancer mortality in Black women
Pyrotinib plus capecitabine promising for HER2-positive breast cancer brain metastases
Pembrolizumab logs 37% improvement in event-free survival in triple-negative breast cancer
CECR2 protein pinpointed as driver of breast cancer metastases
Breast cancer subtypes vary by gene, affecting risk prediction, screening strategies
Olaparib is well tolerated as an additional treatment
Race effects the likelihood to develop lymphoedema following breast cancer treatment
Sentinel lymph node staging is non-inferior to complete axillary lymph node dissection
One in 7 breast cancers detected during screening are overdiagnosed
Using genomics to match treatments improves outcomes
How tamoxifen can induce uterine cancer
Loss of ASXL1 tumour suppressor promotes resistance to CDK4/6 inhibitors
Inducers of ferroptosis are potential drugs to target p53-mutated TNBC cells
MAPK-pathway alterations are associated with resistance to anti-HER2 therapy
Genomic signatures of DCIS define biology and correlate with clinical outcomes
BRCA2 linked to inferior outcomes with CDK4/6 inhibitors plus endocrine therapy
Datopotamab deruxtecan shows promising anti-tumour activity
Trastuzumab deruxtecan outperforms trastuzumab emtansine
Nivolumab plus ipilimumab serve promising dual checkpoint inhibition
Entinostat plus exemestane improves progression-free survival in Chinese patients
Efficacy of pyrotinib plus capecitabine confirmed in previously treated patients
Single-cell spatial analysis can predict response to neoadjuvant immunotherapy
Neoadjuvant pembrolizumab plus chemotherapy benefits event-free survival in TNBC
Early use of ctDNA testing can identify likelihood of relapse in TNBC
Pembrolizumab plus chemotherapy benefits patients with combined positive score ≥10
Neratinib plus trastuzumab plus fulvestrant shows encouraging clinical activity
Addition of palbociclib to standard endocrine therapy does not improve outcome in adjuvant treatment
The SERD elacestrant improves outcomes for patients unresponsive to endocrine therapy
Consistent overall survival benefit of ribociclib in advanced breast cancer
Premenopausal women benefit from adjuvant chemotherapy next to endocrine therapy
Promising anti-tumour activity of the CDK7-inhibitor samuraciclib plus fulvestrant
ctDNA is prognostic and predictive for response to ribociclib plus letrozole
Early switch to fulvestrant plus palbociclib beneficial for patients with ESR1 mutation
Aromatase inhibitors outperform tamoxifen in premenopausal women
Concurrent taxane plus anthracycline most beneficial in reducing risk of breast cancer
Reduced risk of recurrence with ovarian suppression plus tamoxifen/exemestane
Metformin does not improve outcomes in patients with early-stage breast cancer
Omitting sentinel lymph node biopsy improves arm symptoms
GnRHa therapy protects the ovaries of young women with breast cancer having chemo
NOS inhibitor plus taxane promising for resistant triple negative breast cancer
Pyrotinib plus chemo may improve outcomes in pretreated HER2-positive breast cancer
Tumor biology more important than race in predicting treatment response in breast cancer
Breast-cancer patients with estrogen-receptor mutation may benefit from early treatment change
Matching breast-cancer treatments to high-value genomic alterations leads to better outcomes
Elacestrant could become new standard of care for some breast-cancer patients
Long-term safety of GnRHa affirmed in premenopausal women undergoing chemo for breast cancer
Trastuzumab deruxtecan triples PFS
Novel conjugate meets primary endpoint
Longest survival benefit from first-line CDK4/6 inhibitor
Meta-analysis shows 6-months adjuvant trastuzumab is optimal
BrighTNess data may change guidelines
Double-positive results for triple-negative metastatic breast cancer
Survival after neoadjuvant therapy with trastuzumab-lapatinib plus chemotherapy
Postmenopausal breast cancer: extended letrozole reduces recurrence
Asian women also benefit from palbociclib plus letrozole
No PEARLs of survival with palbociclib plus endocrine therapy compared with capecitabine, but QoL better
Women with breast cancer at increased risk for developing atrial fibrillation
Patients with advanced breast cancer denied opportunities to join clinical trials
Acellular dermal matrix not tied to fewer reoperations after breast reconstruction
Eating nuts linked to lower risk of recurrence and death among breast-cancer survivors
Second-line trastuzumab deruxtecan for metastatic HER2-positive breast cancer: Interview with Javier Cortés
Chronic stress hard on women with breast cancer
ESMO 2021 Highlights Podcast
Poor representation in breast-cancer clinical trials tied to real-world harms
Young women who receive left-sided radiation for breast cancer at higher risk for heart disease
Value of carboplatin added to neoadjuvant chemo in triple-negative breast cancer confirmed
Increased breast cancer risk in women with schizophrenia taking certain antipsychotics
In women with breast or ovarian cancer, pathogenic gene variants linked with increased survival
Trastuzumab associated with cardiotoxicity in breast cancer
Breast cancer screening at 40 aids childhood cancer survivors treated without chest radiation
Excellent prognosis for breast cancer patients with ultra-low-risk gene signature
Olaparib benefits early breast cancer patients with BRCA1/2 germline mutation
Platinum-based adjuvant chemotherapy in TNBC is not superior or non-inferior to capecitabine
Dalpiciclib benefits patients with HR-positive, HER2-negative advanced breast cancer
Trastuzumab-deruxtecan showed clinical activity in patients with brain metastases
Novel compound shows promise in lab studies for resistant triple negative breast cancer
Adding neoadjuvant anastrozole to trastuzumab deruxtecan in HER2-low breast cancer
Adjuvant olaparib extends disease-free survival in BRCA carriers
Preventing interstitial lung disease in patients on trastuzumab deruxtecan
T-DXd response on brain metastases in HER2+ breast cancer patients
T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Adding 3 extra years of hormone therapy shows no benefit in breast cancer study
Tumor size, grade tied to long-term survival in selected breast cancer patients
No benefit to routine use of platinum agents after neoadjuvant chemo in triple-negative breast cancer
Prevalence of breast-cancer-susceptibility genes similar in Black and white women
Should the recurrence score for downstaging breast cancer be expanded?
Some patients with HER2-positive early breast cancer might not need chemo
Olaparib cuts odds of invasive disease, death by 42% in some breast cancers
Practicing-changing results for some early-stage BRCA-mutated breast cancers
More breast-cancer patients using complementary medicine than their oncologists realize
Interstitial lung disease a ‘manageable’ side effect of trastuzumab deruxtecan
Primary and recurrent breast tumors may have different HER2 status
Cryoablation may be a promising alternative to surgery for low-risk breast cancer
Breast-cancer survivorship rarely easy, even with early-stage, low-risk disease
Patients on hormonal therapies for cancer should be monitored for heart risk – AHA
SABCS 2020: Updated monarchE trial shows abemaciclib continues to benefit patients with high-risk, HR-positive, HER2-negative, early-stage breast cancer
SABCS 2020: Update from the DESTINY-Breast01 trial
How to avoid chemotherapy overtreatment in breast cancer
SABCS 2020: Adding nivolumab to trastuzumab deruxtecan is well tolerated
Follow-up supports MammaPrint to guide chemo decisions, points to an ‘age effect’
Four healthy eating patterns tied to lower mortality in women with breast cancer
Neoadjuvant chemo may top endocrine therapy in strongly HR-positive, ERBB2-negative breast cancer
Should breast density at age 40 guide mammography screening strategy?
New tool helps predict chemotherapy toxicity in older women with early breast cancer
Could statins protect the heart from breast-cancer chemotherapy?
MRI-based nomograms may predict lymph node metastasis, survival in early breast cancer
Circulating-tumor-cell dynamics have prognostic value in metastatic breast cancer
Breast radiotherapy symptoms often under-recognized by providers
Mastectomy may raise risk of persistent use of opioids, sedative-hypnotics
Trade-offs to skipping radiotherapy after breast-conserving surgery in older women
Some older women with common breast cancer can skip adjuvant chemo
Fertility preservation tied to better reproductive outcomes after breast cancer
Neoadjuvant treatment in patients with high-risk early breast cancer
Prognostic value of tumour infiltrating lymphocytes in young TNBC patients
Contradicting results for chemoimmunotherapy in metastatic TNBC
Second-line sacituzumab govitecan improves survival in metastatic TNBC
Study helps gauge long-term risks for women with DCIS by treatment
Benign breast disease detected after baseline mammogram most apt to become cancer
Genetic test spots high-risk invasive lobular carcinoma
Advanced breast cancer: locoregional therapy does not improve OS
T-DM1 does not improve safety or efficacy in HER-2 positive early breast cancer; favorable iDFS reported
Combination pembrolizumab/chemo improves PFS in metastatic TNBC
Effect of veliparib with or without cisplatin in breast cancer: results of SWOG S1416
PHOEBE, a phase 3 trial comparing pyrotinib and lapatinib in HER2-positive metastatic breast cancer
BYLieve demonstrates efficacy of PIK3CA-directed treatment post CDK4/6-ihibition
Strategies emerge for chemotherapy de-escalation in HER2-positive breast cancer
MRI and 14G biopsies are not accurate enough in pCR detection
No higher pathologic complete response with atezolizumab added to chemotherapy
Anastrozole yields long term effects in the prevention of breast cancer occurrence
S-1 shows promising results in combination with endocrine therapy
Positive effects of adding pertuzumab to trastuzumab + chemotherapy in operable HER2 breast cancer
High rates of ROR-low disease with chemotherapy-free regimen in HR+/HER2- patients
Breast cancer incidence decreased by oestrogen alone but increased by adding progestin
Neoadjuvant + adjuvant pembrolizumab improves pCR in triple-negative breast cancer with lymph node involvement
HER2 antibody-drug conjugate T-DXd promising in T-DM1 pretreated patients
Partial breast irradiation could be as effective as whole breast irradiation
Better outcomes with oral paclitaxel than intravenous paclitaxel in metastatic breast cancer
Higher age means higher risk for breast cancer patients
Sensory peripheral neuropathy after taxane treatment is not uncommon
Subcutaneous pertuzumab + trastuzumab non-inferior to the IV combination
Palbociclib not statistically superior to capecitabine in PFS
Circulating tumour DNA may help predict recurrence in patients with early triple-negative breast cancer
No added benefit for doxorubicin + docetaxel vs doxorubicin + cyclophosphamide
Clinical benefit over trastuzumab for margetuximab in HER2 breast cancer
Residual cancer burden is a predictor for all-type breast cancer patients
Tamoxifen monotherapy may mean undertreatment for some luminal breast cancer patients
Triple negative breast cancer gets positive news: KEYNOTE-522 interim results
CDK4/6 inhibitors change landscape of breast cancer treatment: 2 studies
Veliparib-chemo combo prolongs survival without disease progression in some advanced breast cancer patients
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer
Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer
ImPassion130 brings breast cancer into the immunotherapy era
Discordance of biomarkers in multifocal and lymph node positive breast cancer
Extrapolating data from clinical trials as we treat patients in real life
Letter from the Editor
New Prognostic Biomarkers for Survival Breast Cancer
What is the clinical benefit of treatment of patients with early breast cancer?
Skin and nipple sparing surgery: still a matter of debate
Surgery of the axilla: indications decrease
Gene expression signatures
Adjuvant chemotherapy after neoadjuvant chemotherapy? Going beyond EMA/FDA
Endocrine therapy in premenopausal patients
Endocrine therapy in postmenopausal patients: a graded approach
Selection of patients for neoadjuvant chemotherapy treatment based on oncotype recurrence score in luminal breast cancer
Adjuvant and neoadjuvant therapy: principles and practical considerations
Pregnancy after breast cancer
Chronic Kidney Disease
FLOW-trial: Semaglutide improves kidney and cardiovascular outcomes in type 2 diabetes and chronic kidney disease
Early phase data show albuminuria improvement with avenciguat
Roxadustat shows increases in Hb regardless of prior roxadustat use in CKD
Aldosterone synthase inhibition reduces albuminuria in CKD
Low doses of zibotentan with dapagliflozin improve albuminuria in patients with CKD
Spironolactone failed to reduce major adverse cardiac effects in patients with CKD on haemodialysis
Efficacy of bardoxolone methyl for DKD, without increased cardiac risk
A systems approach to kidney transplantation disappoints
Heart failure: the 2023 update
Cardiovascular disease and diabetes: new guidelines
Protein-bound uremic toxins predict HF events and death in patients with CKD
Checking kidney function is important during the course of IBD
Empagliflozin reduces risk of kidney disease progression and CV events in patients with CKD
Isuzinaxib effective in patients with CKD and T2D
VALOR-CKD trial did not show any benefits for veverimer
EMPA-KIDNEY: empagliflozin slashes kidney disease progression or CV death
Combining UACR and GFR improves prediction of drug effect in CKD phase 2 trials
Dapagliflozin reduces number of hospitalisations in patients with CKD
Novel MSC therapy appears safe and effective in preventing decline in eGFR
Dapagliflozin improves anaemia in patients with CKD with or without T2D
Coaching with a DASH diet improves albuminuria
Selonsertib poses risk of AKI in patients with DKD
Conservative or invasive management for high-risk kidney disease patients with ischaemia?
FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status
Lupus nephritis: Efficient treatment may reduce the risk of kidney disease advancement
New VOYAGER PAD data: Should patients with both PAD and CKD get rivaroxaban?
Sotagliflozin SCORED MACE benefit
PROTECTing renal transplant recipients from uncontrolled gout
Therapeutic approaches in heart failure with diabetes
Antagonising the mineralocorticoid receptor beneficial for patients with diabetes and CKD
2021 ESC Guidelines on Heart Failure
2021 ESC Guidelines on Cardiovascular Disease Prevention
Worse renal function after radical versus partial nephrectomy
Novel mineralocorticoid receptor antagonist effective irrespective of HF history
Increased COVID-19 mortality in patients with cardiorenal comorbidity
Efficacy of dapagliflozin and empagliflozin not influenced by diabetes status
JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA
PAD: Rivaroxaban reduces VTE risk after revascularisation
Finerenone lowers CV events in diabetic CKD patients
Dapagliflozin reduces renal risk independent of CV disease status
DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes
Early trial data shows positive results for treating anaemia in patients with end-stage renal failure
Colorectal Cancer
Retifanlimab boosts survival in patients with anal cancer
NICHE-2 and NICHE-3 show high efficacy of short neoadjuvant immunotherapy in dMMR colon cancer
Organ-preserving regimens in rectal cancer
No benefit of high-dose vitamin D3 supplementation in mCRC
More highlights in Colorectal Cancer
Post-operative MRD status more prognostic than TNM stage
CAPRI 2 GOIM trial navigates biomarker-driven therapy
Meta-analysis of triplet therapy in BRAFV600E-mutated mCRC
CheckMate 8HW: Nivolumab/ipilimumab in MSI-H/dMMR mCRC
Sequence effect for third-line treatment of mCRC
REGINA meets stage 1 endpoint in rectal cancer and moves to stage 2 with reduced dose regorafenib
High efficacy of pembrolizumab combined with standard therapy in patients with MSS/pMMR mCRC and high immune infiltrate
Prognostic value of ctDNA in stage III colon cancer
Neoadjuvant combined immunotherapy also effective in MSS/pMRR CRC
Neoadjuvant immunotherapy plus radiation effective in advanced MSI-H rectal cancer
Peri- or post-operative chemotherapy benefits patients with resectable CRCLM
TRANSMET meets OS endpoint
No survival benefit of tumour debulking for patients with multi-organ metastatic CRC
Thermal ablation of small-size colorectal liver metastases is non-inferior to resection
Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC
Neoadjuvant checkpoint blockade in MSI-H/dMMR CRC
CodeBreaK 300: Promising survival trends in KRAS G12C-mutated mCRC
PREEMPT CRC: Blood-based screening test for colorectal cancer shows promise
Interview: The winding road to curing metastatic colorectal cancer
CheckMate 8HW: Excellent results for nivolumab plus ipilimumab in MSI-H/dMMR mCRC
Can ctDNA-directed therapy improve outcomes in low-risk colon cancer?
Clinical biomarkers may guide therapy selection in RAS wildtype mCRC
Laparoscopic or open surgery in low rectal cancer?
Investigational agent DKN-01 promising for advanced MSS CRC
Neoadjuvant nivolumab/relatlimab demonstrates 100% pathological response in MMRd colon cancer
How to deal with at-risk patients above the CRC screening age limit?
European CRC screening needs to be revised
7-year outcomes of PRODIGE 23 trial
Neoadjuvant chemotherapy may be viable option in locally advanced colon cancer
De-escalation of neoadjuvant treatment of locally advanced rectal cancer is non-inferior
Colorectal cancer: Aspirin and NSAIDs could reduce the risk of early-onset adenomas
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC
Mutation-based selection to identify patients suitable for panitumumab treatment
Fucoidan associated with quality-of-life benefits in patients with rectal cancer receiving CCRT
SUNLIGHT trial meets primary endpoint in refractory metastatic CRC
Does cell-free DNA influence MRD testing in post-operative colon cancer?
OPERA: surgery may be avoided with adequate therapy in rectal cancer
Can we improve total neoadjuvant therapy for rectal cancer?
Computer-aided colonoscopies improved adenoma detection rates
Benefit of colon cancer screening with colonoscopy lower than anticipated
Screening-detected colorectal cancers may have superior surgical outcomes
High pathological responses to neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer
Fruquintinib: a potential new treatment for patients with refractory mCRC
Second-line avelumab is effective in patients with MSI-H/dMMR mCRC
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer
Spectacular results for dostarlimab in mismatch repair deficient rectal cancer
Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases
NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC
Dostarlimab may offer an alternative for dMMR rectal cancer
DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC
Key updates in colorectal cancer screening
Impact of COVID-19 on screening for colorectal cancer
Nivolumab plus standard-of-care does not meet primary endpoint for mCRC
No benefit of additional oxaliplatin in elderly patients with mCRC
Prognostic impact of early oxaliplatin discontinuation in colon cancer unravelled
Long-course chemoradiation versus short-course radiotherapy in rectal cancer
Analysis of metastasectomy in CRC reveals benefits and disparities
EPOCH trial: Subgroup analyses and additional endpoints for TARE plus chemo
Neoadjuvant chemotherapy potential alternative to neoadjuvant chemoradiotherapy in LARC
Immune chemo-sensitisation looks promising in microsatellite-stable mCRC
Adagrasib shows promising clinical activity in heavily pretreated KRAS-mutated CRC
Automated detection of microsatellite status on unstained samples in early colon cancer
Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer
Panitumumab added to 5-FU/LV effective as maintenance therapy in patients with mCRC
Trastuzumab-deruxtecan showed promising activity in patients with HER2-expressing mCRC
Increased risk of rectal cancer after colectomy in IBD
Risk of colorectal cancer is detected by low-pass whole genome sequencing
First-line pembrolizumab shows superior PFS in MSI-H/dMMR mCRC
Short-course radiotherapy with delayed surgery better for elderly rectal cancer patients
Circulating tumour DNA predicts recurrence in colorectal cancer
Neoadjuvant pembrolizumab in locally-advanced rectal cancer: primary results
Prognostic value of tumour deposits in stage 3 colon cancer patients
Ipilimumab/nivolumab plus panitumumab in patients with microsatellite-stable mCRC
Preliminary surgery salvage data after watch & wait policy from OPERA trial
Predicting resistance to first-line FOLFOX plus bevacizumab in mCRC using circulating markers
Final OS analyses comparing trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line unresectable mCRC patients noneligible for intensive therapy
Maintenance treatment with cetuximab versus observation in RAS wildtype mCRC
Duloxetine ameliorates oxaliplatin-induced peripheral neuropathy
Rechallenge of RAS/BRAF wildtype CRC with avelumab plus cetuximab
Adjuvant chemotherapy less effective in elderly CRC patients
Post-colonoscopy colorectal cancers in IBD patients
Pembrolizumab as first-line in MSI-H mCRC
Risk of rectal, anal cancer increased in perianal CD
Mixed data: AMG 510 in tumours with KRASG12C
Preoperative chemotherapy for colon cancer
Liquid biopsy identifies relapse in patients with colorectal cancer after surgery
Advanced colorectal cancer and BRAF mutations: triplet combination improves survival
Ramosetron relieves low anterior resection syndrome
Global burden of digestive diseases reveals alarming trends
IBD prevalence 3 times higher than estimated and expected to rise
First-in-human study shows IL1RAP-targeting drug safe in solid tumours
Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD
Shallow whole-genome sequencing predicts future cancer risk of LGD in UC
Significantly increased risk of CRC and/or HGD after appendectomy in UC
Coronary Artery Disease
GLORIOUS: GLP-1 agonist did not meet primary endpoint in CABG
Guidelines for the management of chronic coronary syndromes
EPIC-CAD: What is the best antithrombotic approach in high-risk AF plus stable CAD?
ABYSS: Can beta-blocker safely be interrupted post-MI?
SWEDEGRAFT: Can a no-touch vein harvesting technique improve outcomes in CABG?
Bioadaptor meets expectations in reducing target lesion failures in coronary artery disease
REC-CAGEFREE I: Can we avoid permanent stenting with drug-coated balloons?
OCCUPI: OCT-guided PCI improves outcomes in complex CAD
NOTION-3: TAVI plus PCI improves outcomes in CAD plus severe aortic stenosis
Preventive PCI of vulnerable intracoronary plaque leads to favourable outcomes
REPRIEVE: Mechanisms behind MACE reduction in HIV population on pitavastatin
MINT: Liberal or restrictive transfusion strategy in MI with anaemia?
ORBITA-2 confirms PCI effective for symptom relief in patients with stable angina
Nicotinamide riboside shows promising trend for walking function in PAD
Pemafibrate reduces microvascular complications of PAD and T2D
Dapagliflozin improves cardiometabolic outcomes in myocardial infarction
Immediate or staged revascularisation in STEMI plus multivessel disease?
Lp(a) and cardiovascular events: which test is the best?
No benefit of extracorporeal life support in MI plus cardiogenic shock
Functional revascularisation outperforms culprit-only strategy in older MI patients
Guidelines for Acute Coronary Syndrome
Can aspirin be omitted after PCI in patients with high bleeding risk?
Angiography vs OCT vs IVUS guidance for PCI: a network meta-analysis
DAPT or clopidogrel monotherapy after stenting in high-risk East-Asian patients?
OCTOBER trial: OCT-guided PCI improves clinical outcomes in bifurcation lesions
Immediate complete revascularisation non-inferior to staged complete revascularisation
RENOVATE-COMPLEX-PCI results support intravascular-guided PCI for complex lesions
PCI not better than GDMT in severe ischaemic cardiomyopathy
Evolocumab improves coronary plaque morphology in stable CAD
Grafting with the radial vein: an underrated option in CABG surgery?
RESPECT-EPA misses primary endpoint but hints towards improvements in CV outcomes by EPA
Evolving evidence for P2Y12 inhibition in chronic coronary syndromes: PANTHER
Danish study suggests starting CVD screening before age 70
Long-term therapy with evolocumab associated with lower CV mortality
Medical therapy versus PCI for ischaemic cardiomyopathy
Allopurinol disappoints in ALL-HEART
Conservative or invasive management for high-risk kidney disease patients with ischaemia?
Genotype-guided antiplatelet therapy in patients receiving PCI
Coronary CT angiography diagnostics compared head-to-head
FFR-guided decision-making in patients with AMI and multivessel disease
Signs of heart disease may be more subtle in women than in men
New VOYAGER PAD data: Should patients with both PAD and CKD get rivaroxaban?
COMPLETE revascularisation improves angina-related QoL
Plot twist for negative FAME 3 results: early QoL benefits of PCI
Chocolate Touch vs Lutonix catheters
No FLAVOUR difference between FFR and IVUS for PCI guidance
Lipoprotein(a) slashed by 98% in APOLLO trial
ACS patients with several metabolic risk factors may benefit most from PCSK9 inhibitors
Co-prescribed PDE5 inhibitors and nitrates not tied to adverse outcomes
Serious mental illness tied to increased CV risk, starting in young adulthood
CT as effective as invasive angiography for guiding treatment of stable chest pain
Conflicting periprocedural MI definitions impact clinical practice, research
Pilot trial shows potential benefit of stem-cell therapy in microvascular dysfunction
Apixaban plus P2Y12 inhibitor likely best for AF after ACS or PCI
Whether treated with CABG or PCI, heavily calcified lesions tied to higher mortality
Early surgery outperforms conservative management in asymptomatic severe aortic stenosis
External support device for SVG grafts in CABG surgery shows promise
Carefully selected patients can go home the day after PCI for STEMI
Extracoronary vascular events likely rare after spontaneous coronary artery dissection
Time from stopping blood thinner to CABG can be safely shortened
Bypass still better than stenting in severe heart disease – study
Coronary calcium score alone of limited value in younger patients with suspected CAD
Adding rivaroxaban to aspirin may help some CAD, PAD patients live longer
Men and women benefit equally from early aspirin withdrawal following PCI
Better outcomes with invasive strategy if anatomic complete revascularisation is possible
PCI for chronic total occlusion more successful after coronary CTA
Subgroup of patients with high heart rate response and coronary artery disease benefit from CPAP
Lower burden of high-risk atherosclerotic plaques in psoriasis patients treated with biologics
PCI for in-stent chronic total occlusion shows in-hospital success
Benefits of multivessel PCI unclear in patients with NSTEMI and cardiogenic shock
Bleeding, vascular complication rates lower when transradial PCI replaces transfemoral PCI
Higher bleeding risk in women after PCI mostly due to baseline sex differences
No age cap for lipid-lowering therapy
Cancer patients have higher readmission rates for heart attack, bleeding after PCI
Extra imaging reveals cause of MINOCA in women
Ticagrelor not superior to clopidogrel after elective PCI
Long-term mortality after coronary-artery occlusion may not depend on recanalization status
Benzodiazepines given for ACS anxiety, pain may trigger posttraumatic stress symptoms
Calcium chloride during CABG curbs subsequent atrial fibrillation
DASH-diet intervention might slow progression of nonobstructive coronary atherosclerosis
Higher levels of diet-derived antioxidants don’t protect against heart disease
Trimetazidine after successful PCI not associated with fewer cardiac events
Low-dose colchicine reduces CV death and ischaemic events in coronary disease
Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients
Reduced progression of coronary atherosclerosis with icosapent ethyl
Mortality lower after coronary bypass surgery than after percutaneous interventions
Intravascular lithotripsy safely treats severely calcified coronary-artery disease
Fewer adverse events with ticagrelor monotherapy after 3 months DAPT
TWILIGHT sub-study: same outcomes for diabetes patients
TWILIGHT sub-study: complex PCI patients
Apixaban in AF patients with recent ACS/PCI: Drop aspirin after 30 days
Radial artery best for second bypass
PCI and CABG are equal in left main CAD
TAILOR-PCI misses endpoint but still provides valuable insights
Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy
Immediate coronary angiography after cardiac arrest does not improve survival
Complete revascularisation for obstructive non-culprit lesions with vulnerable plaque
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI
Intra-aortic balloon pump better than Impella: new observational data
ISCHEMIA trial: Invasive treatment only better for angina burden
Patients with polyvascular disease significantly undertreated with lipid lowering therapies
COVID-19
COVID-19 infection associated with higher MS relapse rate
Women at higher risk of functional respiratory complaints following a COVID-19 infection
Elevated myeloid inflammation and complement activation present in various phenotypes of long COVID
New study characterises brain fog
Amantadine in early COVID-19 enhances recovery
SARS-CoV-2 vaccination in CIDP and MMN: more benefit than harm
How to manage arterial thrombosis and thromboembolism in COVID-19?
COVID-19: Young adults with auto-immune diseases have different risks than their healthy counterparts
Original antigenic sin influences humoral immune response to SARS-CoV-2
COVA trial: success for the investigational agent sarconeos in hospitalised COVID-19
Mitochondrial DNA levels predict COVID-19 severity
Anticoagulation in non-critically ill hospitalised COVID patients
Drop in overall IBD procedures during the pandemic
Highly increased risk of arrhythmias after mechanical ventilation for COVID-19
Evidence-based advocacy for people affected by brain tumours
‘No’ to routine use of rivaroxaban in outpatients with COVID-19
COVID-19 pandemic: Older adults and those affected by the delta variant experienced increased cardiovascular morbidity and mortality
COVID-19 mRNA vaccination does not amplify risk of cardiovascular hospitalisation
COVID-19 and MS: lessons learned thus far
Ocrelizumab and fingolimod increase the risk of COVID-19 and of worse outcomes
Humoral and cellular immune responses after SARS-CoV-2 vaccination
SARS-CoV-2: Booster doses of key importance for cirrhotic patients
Lack of vaccination results in a higher frequency of pre-term births in pregnant women with rheumatic disease and COVID-19
Does vilobelimab reduce mortality in severe COVID-19?
Awake proning not positive in COVID-19
Favipiravir may help patients over 60 years with COVID-19 to recover
Brensocatib fails in severe COVID-19
Inhaled agent under investigation for COVID-19
Accurate voice-based COVID-19 diagnostic test in development
Novel scoring tool for post-COVID syndrome aids clinicians and researchers
COVID-19 elevates risk of neurodegenerative disorders
More headaches in adolescents during COVID-19 pandemic
AstraZeneca vaccination and risk of cerebral venous sinus thrombosis
Large impact of COVID-19 on dementia diagnosis and care
Social distancing led to a reduced number of exacerbations in bronchiectasis patients
SPRINTER: SNG001 still in the running?
Nebulised aviptadil “futile” in I-SPY COVID-19 trial
Lung transplantation after COVID-19-associated ARDS
COVI-PRONE trial on its back
Mesenchymal stem cells offer no benefit in COVID-19
Alpha-1 antitrypsin for ARDS secondary to severe COVID-19
Frailty prevalent 5 months following hospitalisation for COVID-19
Paediatric long COVID lacks definitions
Longer time between COVID shots may protect young men from heart inflammation
Use of statins for primary prevention tied to lower risk of hospitalization for COVID-19
Neurological symptoms of COVID-19 can last months
COVID-19 increases the mortality rates of patients with ALD
Cognitive, EEG, and MRI features in COVID-19 survivors
Neurological manifestations of COVID-19 worsen prognosis
New evidence for biological basis of “COVID-19 brain fog”
Impact of COVID-19 public health interventions
Telemedicine during COVID-19 pandemic highly appreciated
COVID vaccination especially important for dialysis patients
‘Startling’ heart attack finding in COVID patients
AD treatment during the pandemic: dupilumab does not raise COVID-19 infection risk
Lessons from the COVID-19 pandemic for IBD management
Impact of COVID-19 on screening for colorectal cancer
ACC issues consensus document on cardiovascular consequences of COVID-19
Alzheimer’s-like changes seen in COVID-19 patients’ brains
DLQI scores underestimated during lockdowns?
TNF blockers likely beneficial for psoriatic patients with COVID-19
Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion
COVID-19 vaccines seem safe, generally well tolerated in rheumatic, musculoskeletal diseases
Blood pressure control disrupted during the pandemic
Icosapent ethyl did not reduce the risk of hospitalisation in COVID-19
Neutral effect of P2Y12 inhibitors in non-critical COVID-19 hospitalisations
COVID-19 mRNA vaccination benefits outweigh the risk for myocarditis
Vaccine booster improves immune response in patients treated with rituximab
Vaccinated rheumatic patients carry increased risk for COVID-19 breakthrough infections
B-cell depleting medication increases COVID-19 breakthrough infection outcome risk
COVID-19 mRNA vaccine safe and tolerable in adults with autoimmune disease
Lupus patients less protected by COVID-19 vaccine
Laboratory and clinical signs 24h after hospitalisation predict MIS-C in children
MS patients at risk of hampered immune response after vaccination
Immunotherapy in MS does not influence COVID-19 severity and mortality
Anti-CD20 antibodies associated with worse COVID-19 outcomes
ECTRIMS-EAN consensus on vaccination in MS patients
Apixaban tops rivaroxaban for repeat-VTE protection in real-world analysis
Study reveals spectrum of COVID-19 brain complications
Cardiopulmonary exercise test helps define the cause of unexplained dyspnea in COVID long-haulers
Connecting, challenging, and empowering youth through their smartphone
Alcohol consumption during lockdown
Post-COVID-19 depression responds well to SSRIs
Impact of COVID-19 on patients with psychotic disorders
‘Glimpse of hope’ when anti-CD20 drugs limit vaccine antibodies
Dupilumab for atopic dermatitis linked with milder COVID-19 symptoms
Adequate response to SARS-CoV-2 vaccine in cancer patients
Cancer patients more likely to die from COVID-19 when hospital admittance is required
Third global survey of the ESMO Resilience Task Force
High COVID-19 mortality in Swiss cancer patients
Damaged skin as a possible transmission route for SARS-CoV-2
Anti-TNF therapy tied to better outcomes in IBD patients with COVID-19
Higher inflammation markers in COVID-19 patients with a first negative PCR test
Persistent fatigue following COVID-19
Risk of COVID-19-related morbidity and mortality in young and middle-aged adults
Impact of COVID-19 on the dynamics of respiratory viruses
The effect of the pandemic on the discharge diagnosis of older COPD patients
Dynamics of environmental pollution during and after COVID-19 lockdown
Telemedicine beneficial for headache care during the pandemic
Comparison of headaches after SARS-CoV-2 vaccination
Grey matter cortical changes in patients with persistent headache after COVID-19
Increased risk of cerebral venous thrombosis in COVID-19
Two-dose COVID-19 vaccination may not lead to flares in RA patients
More adults embraced at-home colorectal-cancer screening during pandemic
Serologic response to COVID-19 mRNA vaccine reduced in IBD patients on anti-TNFα
Rivaroxaban improves clinical outcomes in discharged COVID-19 patients
COVID-19: Thromboembolic risk reduction with therapeutic heparin dosing
Long COVID symptoms – Is ongoing cardiac damage the culprit?
UEGW 2021 Highlights Podcast
ECNP 2021 Highlights Podcast
EADV 2021 Highlights Podcast
COVID toes and seasonal chilblains share similar immune responses
B-cell-targeted therapy linked with severe COVID-19 among patients with arthritis
Increased risk of death in cardiac wait list patients seen early in pandemic
GLCC survey: Increased demand for patient-support services during COVID-19 pandemic
Psoriasis registries yield important data about COVID-19
COVID-19 affects patients and care
Vaccination feasible in people with psoriatic disease
Low COVID-19 risk for patients with psoriasis on biologic treatment
Lung-cancer trial enrollment takes a hit amid COVID-19
Vaccines induce antibodies despite cancer, immunocompromise
Telemedicine: Every light has its shadow
COVID-19-related HF: from systemic infection to cardiac inflammation
Increased COVID-19 mortality in patients with cardiorenal comorbidity
Myocardial infarction outcomes were significantly affected by the pandemic
COVID-19 in AF patients with HF: no higher mortality but longer hospital stay
Severe outcomes of COVID-19 in patients with dementia
First evidence of brainstem involvement in COVID-19
Intracerebral haemorrhage only slightly increases mortality in COVID-19 patients
Cognitive/behavioural alterations persistent after COVID-19
Neural base of persistent hyposmia after COVID-19
Neurological symptoms and complications of COVID-19 affect outcomes
COVID-19 patients with B-cell malignancies may deteriorate on bamlanivimab-etesevimab therapy
Decline in hospitalizations for heart attack and stroke persisted through 2020
Physiopathology of coagulopathy in haematological malignancies and COVID-19
Haemostatic abnormalities are associated with mortality in COVID-19
Mechanisms of COVID-19 vaccine-induced thrombotic thrombocytopenia
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: discovery and diagnosis
Rituximab or JAK inhibitors increase the risk of severe COVID-19
Immunomodulatory therapies for severe COVID-19: literature update
Hair shedding related to COVID-19 doesn’t last long
Vector-based vaccines likely more effective in patients on rituximab
Blistering eruptions, including bullous pemphigoid, seen after COVID vaccine
Methotrexate use tied to weakened antibody response after first Pfizer-BioNTech vaccine shot
Pfizer/BioNTech COVID-19 vaccine seems effective, safe in HCT, CART therapy patients
Dapagliflozin fails to show a significant protective effect in COVID-19
Therapeutic anticoagulation not superior to prophylactic anticoagulation in COVID-19
Atorvastatin does not reduce mortality in COVID-19
Does COPD plus COVID-19 equal higher mortality?
Association between positive airway pressure treatment adherence and COVID-19 infection rates
Antibody treatment for COVID-19: a combination is successful
Air pollution: an underestimated negative prognostic factor for COVID-19
Healthcare workers vulnerable to SARS-CoV-2 infections
Genetic risk variants responsible for COVID-19 predisposition
No increased risk of (severe) COVID-19 among IBD patients
SARS-CoV-2 may exploit injured kidney cells to cause infection, damage
Limited added value of ECG-based mortality prediction in COVID-19 patients using machine learning
The neurological impact of COVID-19
Chemosensory dysfunction often persistent after COVID-19
Pandemic results in decreased global stroke care
Stroke uncommon in critically ill COVID-19 patients
Neurologic symptoms in children with multisystem inflammatory syndrome
COVID-19 could cause novel seizures in patients without epilepsy
Non-invasive ventilation tied to higher mortality than CPAP in COVID-19 pneumonia
Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on
COVID-19 in children – cutaneous involvement is common
Psoriasis management in times of COVID-19: the knowledge is growing steadily
Cutaneous reactions after COVID-19 vaccination: an update
Patients with autoimmune disease may not be fully protected even after second COVID shot
Non-live COVID-19 vaccines likely safe, effective in MS patients, but immune response varies
mRNA COVID-19 vaccines effective in IBD patients receiving biological therapies
Do anti-CD20 DMTs cause worse COVID-19 outcomes in MS?
Transplant saves selected patients with irreversible COVID-19 lung disease
Pfizer-BioNTech COVID-19 vaccine appears safe in cancer patients on immunotherapy
COVID-19 outcomes no worse with congenital heart disease
COVID-19 impact on gastrointestinal cancer care
Treatment delay for cholangiocarcinoma adjuvant therapy does not affect OS
Outcomes with COVID-19 acute kidney injury worse than for other AKI patients
More complicated course of COVID-19 in leukaemia patients
Older age and imatinib treatment associated with COVID-19 mortality in CML
Allogeneic SARS-CoV-2-specific T cells to treat COVID-19
Fewer CV complications than expected in AHA COVID-19 Registry
Worse COVID-19 outcomes in younger obese patients
Effects of CVD in hospitalised COVID-19 patients
Meta-analyses: ACEI/ARB and COVID-19
Unfavourable outcomes for COVID-19 patients with AF and atrial flutter
COVID-19 survival poor for hematopoietic stem cell transplant recipients
COVID has led to a drop in lung cancer diagnosis, more deaths
COVID outcomes have improved over time in patients with rheumatic disease
COVID-19 in patients with rheumatic disease: most report mild disease
Poor disease control: a risk factor for severe COVID-19
No heightened outcome risk for rheumatic patients with COVID-19
Children with rheumatic disease have no greater risk of a COVID-19 infection
Insufficient antimalarial supply for rheumatic disease treatment in the early COVID-19 pandemic
COVID-19 far more deadly than seasonal flu, large study confirms
Biologic psoriasis treatment and COVID-19 risk: Contradictory results
Much to be learned about COVID-19 and the skin
Anti-cytokine therapy normalizes ACE2 expression in IBD, may protect against COVID-19
COVID-19: Continuing versus suspending ACE inhibitors and ARBs
Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan
The Yale COVID-19 Cardiovascular Registry
COVID-19 treatments and the importance of randomised trials
Mental health during the COVID-19 pandemic
Endoscopy can be delivered safely during the COVID-19 pandemic
Risk factors for severe COVID-19 among IBD patients
COVID-19 infections: Bronchoscopy provides additional diagnostic certainty
COVID-19 vaccines: An ongoing race
COVID-19: What is the risk of reinfection?
COVID-19 App: The Dutch experience
Secondary pulmonary fibrosis: a possible long-term effect of severe COVID-19
COVID-19 survivors benefit from structured follow-up
Early pulmonary rehabilitation post-COVID-19 aids recovery
COVID-19-associated delays in aortic-valve replacement tied to worse outcomes
Treatment times of acute STEMI have increased with COVID-19 pandemic
Crosstalk between inflammation and coagulation in severe COVID-19 infections
COVID-19 associated with higher VTE rates relative to influenza
Therapeutic anticoagulation not associated with lower mortality rates in COVID-19 ICU patients
COVID-19 not associated with heightened VTE risk after discharge
Endothelial damage in COVID-19
Thoracic cancers versus COVID-19
Crohn's Disease
Antibody responses predict IBD onset 10 years before diagnosis
Therapeutic antibody clearance reliable predictor for endoscopic outcomes in CD
Higher neoplasia detection rate with virtual chromoendoscopy in real-world IBD study
Reducing the carbon footprint of IBD care
TL1A-LTB axis induces perianal fistulising disease-associated changes in CD
Emulsifier-restrictive diet effective in alleviating symptoms in CD
Could stem cell transplantation be a fruitful solution for refractory CD?
Improving efficacy with longer mirikizumab treatment in CD
Latest data for subcutaneous guselkumab in CD and UC
VEDOKIDS: Long-term outcomes of vedolizumab in paediatric IBD
PREdiCCT: Role of psychosocial factors in IBD flares unravelled
Kono-S or side-to-side anastomosis for resection in Crohn’s terminal ileitis?
ECCO consensus on diet and nutrition in IBD
A paradigm shift in CD clinical practice
LOVE-CD: Vedolizumab yields better outcomes in early than in late CD
Moving towards the prevention of IBD
New insights into perianal fistulising CD pathogenesis may lead to new therapies
Risankizumab influences key pathogenic Th17 cells in CD
Extending ustekinumab dosing interval does not influence drug survival in IBD
CULTIVATE: Promising signal for etrasimod in Crohn’s disease
GALAXI 2 & 3: Guselkumab proves efficacy in Crohn’s disease
VEDOKIDS: Vedolizumab maintains remission in patients with paediatric IBD
ADMIRE-CD II: Darvadstrocel does not meet primary endpoint in complex Crohn’s perianal fistulas
VIVID-1: Mirikizumab meets expectations in Crohn’s disease
SEQUENCE: Risankizumab versus ustekinumab across endpoints
Fatigue, urgency, and QoL improvements on mirikizumab in Crohn’s disease
PROFILE: Top-down treatment strategy benefits patients with early Crohn’s disease
Ustekinumab as alternative for anti-TNFs in HLA-DQA1*05-positive Crohn’s disease
How effective is dose escalation of biologicals in IBD?
Promising data for JAK inhibitors in Crohn’s disease from phase 2 trial
U-ENDURE long-term extension: sustained efficacy of upadacitinib in Crohn’s disease
Should we screen for metabolic bone disease at IBD diagnosis?
Clear case for NUDT15 genetic testing in Asian patients with IBD
HELIOS: HD-WLE can yield similar neoplasia detection rates as HD-CE
CURE-CD: Capsule endoscopy-guided proactive treatment leads to fewer relapses in Crohn’s disease
Extended mesenterectomy or mesenteric-sparing surgery in Crohn’s disease?
Similar outcomes for Kono-S and side-to-side anastomosis in Crohn’s terminal ileitis
Risk factors for re-resection in Crohn’s disease revealed
ADMIRE-CD-II: Darvadstrocel does not meet primary endpoint in complex peri-anal fistula
DIVERSITY1: Filgotinib results in Crohn’s disease leave investigators puzzled
SEQUENCE: Risankizumab doubles endoscopic remission rates compared with ustekinumab in CD
Risankizumab resolves extraintestinal manifestations in CD
Rapid response to upadacitinib boosts outcomes in severe Crohn’s disease
Reprogramming stem cells to heal intestinal mucosa in IBD: fact or fiction?
Linking the Black Death with Crohn’s disease predisposition
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease
Environmental and dietary factors can amplify paediatric IBD risk
Crohn’s disease: Upadacitinib improves endoscopic outcomes in participants with or without previous biologic failure
Checking kidney function is important during the course of IBD
Diabetes therapy with GLP-1-based drugs does not elevate the risk of IBD
Long-term resection potentially better than anti-TNF treatment in CD
Early, post-operative complications in CD reduced by pre-operative enteral nutrition, irrespective of biologic exposure
Perinatal period is crucial for the risk of developing CD
Drop in overall IBD procedures during the pandemic
Early-life antibiotic exposure: a risk factor for paediatric-onset IBD
Proton pump inhibitors associated with worse outcomes in CD
Paediatric patients with immune-mediated inflammatory disease harbour a heightened cancer risk
Poor sleep in CD linked to low levels of vitamin D
Anti-TNF withdrawal may be a safe option in stable IBD
Favourable maintenance rates for risankizumab also in delayed responders with CD
Upadacitinib for CD: remarkable efficacy in induction therapy
Pivotal results of etrolizumab for CD partly disappointing
Better results for vedolizumab in early CD
Some patients with limited CD may benefit from an early surgical intervention
Dose-interval of adalimumab might be prolonged in CD patients in stable remission
High prevalence of fibromyalgia in patients with inflammatory bowel disease
Antibiotic use elevates IBD risks in senior citizens
Too much hygiene: CD in later life?
Biologic treatment decreases dementia risk in senior IBD patients
CD: Induction treatment with upadacitinib successful in clinical and endoscopic ratings
Lessons from the COVID-19 pandemic for IBD management
Multi-Omic and dietary analysis of Crohn’s disease identifies pathogenetic factors
Novel classification system for perianal fistulising Crohn’s disease
Vaccination tool associated with improved vaccination coverage in IBD
Comparable safety profiles of biological therapies in elderly patients with IBD
Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease
Segmental colectomy beneficial over total colectomy in Chrohn’s disease
Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease
VEDOKIDS: Vedolizumab seems effective in paediatric IBD
Primary endpoint of 5-hydroxytryptophan for fatigue in IBD not met
Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease
Subcutaneous infliximab versus subcutaneous vedolizumab in IBD
Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease
Risankizumab more efficacious in colonic than in ileal Crohn’s disease
Filgotinib seems promising for perianal fistulising Crohn’s disease
Women with IBD expect their gastroenterologist to initiate discussion of reproductive health
Crohn’s strictures may respond to immunosuppressive drug therapy
Simple scoring system may safely reduce abdominopelvic CT in Crohn’s patients
Crohn’s disease exclusion diet may produce remission of mild-to-moderate disease
Anti-TNF therapy tied to better outcomes in IBD patients with COVID-19
Assisted reproductive therapy safe in women with IBD but efficacy mixed
Risankizumab meets primary endpoints in maintenance study for CD patients
Ustekinumab treat-to-target strategy offers long-term alternative for standard-of-care in CD
Serologic response to COVID-19 mRNA vaccine reduced in IBD patients on anti-TNFα
Serious adverse events put a stop to ASTIClite trial for CD
Home infusion safe for IBD patients receiving infliximab and vedolizumab
UEGW 2021 Highlights Podcast
Live varicella-zoster vaccine safe, effective with TNF inhibitors
Could steroid treatment speed recovery from infliximab-induced liver injury?
Subcutaneous vedolizumab appears effective maintenance therapy in Crohn’s disease
Adalimumab biosimilar on par with original in Crohn’s disease
New target to dial down inflammation and pain discovered
TAVI safe and effective in patients with inflammatory bowel disease
Pfizer-BioNTech vaccine effectiveness comparable in IBD patients, general population
No increased risk of (severe) COVID-19 among IBD patients
Blood proteins predicting relapse in CD identified
Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD
Extracellular RNA has potential as a non-invasive biomarker in IBD
Ustekinumab safe and effective in elderly CD patients
Early clinical remission and response following risankizumab therapy in CD
Surgical closure plus anti-TNF outperforms anti-TNF alone for perianal fistula
Increased risk of rectal cancer after colectomy in IBD
Risk of hospitalisation and surgery linked to IBD biological
Risk of colorectal cancer is detected by low-pass whole genome sequencing
Large variability in IBD care and education across Europe
Ultra-processed food intake associated with IBD
Factors of coping difficulties in IBD revealed
Obesity increases the risk of immunogenicity to adalimumab in IBD
Contrast-free imaging can spot post-op Crohn’s recurrence
Specific carbohydrate diet not superior to Mediterranean diet for Crohn’s disease
Stopping infliximab linked to relapse in ulcerative colitis
mRNA COVID-19 vaccines effective in IBD patients receiving biological therapies
IBD patients should be screened for anxiety, depression
Reassuring data on immune checkpoint inhibitors in autoimmune disease
Adherent-invasive E. coli metabolism drives inflammation in Crohn’s disease
Hirschsprung disease tied to increased risk of inflammatory bowel disease
IBD patients with clinical remission often malnourished, sarcopenic
IV ferric carboxymaltose tops IV iron sucrose for iron-deficiency anemia in IBD
Cigarette smoke tied to colorectal neoplasia in IBD patients
Anti-cytokine therapy normalizes ACE2 expression in IBD, may protect against COVID-19
Race, ethnicity affect epidemiology and management of inflammatory bowel diseases
Sustained efficacy of mirikizumab in moderate-to-severe Crohn’s disease
Post-colonoscopy colorectal cancers in IBD patients
Risk factors for severe COVID-19 among IBD patients
First randomised T2T trial using endoscopy to guide dose escalation
IBS symptoms common in patients with IBD in remission
Resolution of mucosal inflammation has dramatic effect
Role of immune cells in intestinal fibrosis
Association between meat consumption and IBD risk
Increased risk of small bowel cancer in IBD
On the cutting edge of pathology and surgery
Impact of strategies on intestinal resection rate
Early ileocaecal resection in CD patients failing conventional treatment
Biologics before surgery in IBD do not elevate infection risk
Ustekinumab in CD: a T2T trial
Subcutaneous vedolizumab maintenance therapy in CD
Vedolizumab treatment persistence and safety
Pipeline of IBD drugs
Open-label extension study of risankizumab: final results
Clinical remission after dose escalation of upadacitinib
Multi-omics help describe CD phenotypes
The positive impact of genetic data on drug development
Practice-changing: infliximab in children with Crohn’s
Ileal microbiota predict recurrence in CD patients after resection
Decreased microvilli length in CD patients
Phase 2 data shows benefit for mirikizumab in CD patients
Half of common medications wreak havoc on gut microbiome
Global burden of digestive diseases reveals alarming trends
IBD prevalence 3 times higher than estimated and expected to rise
Haematopoietic stem cells can sense tissue damage in the gut
The right drug for the right patient
Topical review
Complementary and alternative medicine associated with chronic fatigue and lower QoL
Selective oral sphingosine 1-phosphate receptor modulator amiselimod
Vedolizumab: Results from the GEMINI programme
Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease
Novel host-microbiome interactions in inflammatory bowel disease
Pathogenesis
The costs and benefits of biologicals
Ustekinumab as maintenance therapy and with shortened interval
Early remission of Crohn’s disease prevents progression
Microbial composition and psychological wellbeing
Immune cells and microbes: a happy marriage?
Efficacy and safety of biosimilars
Gene expression signature predicts non-response
OPERA II study: MAdCAM-1 antibody SHP647
IBD risk of treatment with IL-17 antagonists
Proactive adalimumab trough measurements
Glycans as novel immunomodulators in inflammatory bowel disease
Quiescent disease, characteristics and biomarker correlations
Enhanced post-operative recovery pathways for IBD patients
Combining new drugs with different mechanisms
Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD
Vedolizumab in anti-TNF-naïve IBD patients and safety profile
Cancer risk in IBD associated with age and recent immunomodulator use
Significant reduction of emergency stoma surgeries for CD
Central role of IL-23 in molecular resistance to anti-TNF therapy
Early and significant effects with upadacitinib induction treatment
Vedolizumab induces endoscopic remission and healing in refractory CD
Targeting early disease: lessons from rheumatoid arthritis
SHP647 is efficacious and well-tolerated in CD
Integration of “omics” and potential for clinical practice
Higher rates of remission and healing with vedolizumab vs TNF antagonist
Comparative effectiveness of vedolizumab and ustekinumab in CD
Diagnostic techniques for IBD: the ECCO-ESGAR Guidelines
Depression
Innovative app boosts mental health in patients with RA
Anxiety and depression: Lifestyle influential in MACE prevention
HF patients with metabolic dysfunction at high risk to develop depressive symptoms
Worse self-management in patients with inflammatory arthritis in the presence of comorbid anxiety or depression
Zuranolone shows rapid-acting efficacy in postpartum depression
Mode of action of psilocybin
Fast and sustained effect of 2 administrations of psilocybin on depression
Comorbid anxiety and depression may benefit from psoriasis treatment with certolizumab
Targeting cortical activation by transcranial magnetic stimulation
Comorbid depression comes with a profoundly higher mortality risk in RA
Depression and brain structures associations across a lifespan
BDNF/TrkB pathway promising alternative for new antidepressants
Zuranolone reduces symptoms of major depression
Vortioxetine effectively reduces symptoms of depression and anxiety
Esketamine outperforms real-world management for treatment-resistant depression: preliminary results
Post-COVID-19 depression responds well to SSRIs
Impact of COVID-19 on patients with psychotic disorders
Cannabidiol for cannabis cessation shows positive results
ECNP 2021 Highlights Podcast
Possible aetiologies for COPD exacerbations – more evidence is needed
Personalised medicine in depression: a realistic way forward?
Heart rate could be a potential biomarker for depression
The PRISM project: focusing on biological parameters across neuropsychiatric disorders
Baby’s heart rate shows stress if their mother is depressed or anxious
Similar treatment needs for high-frequency episodic and low-frequency chronic migraine
Depression closely related to fatigue in SLE patients
Depressive symptoms associated with increased stroke risk
Microbial composition and psychological wellbeing
Diabetes
DPP-4 is better target to lower migraine rates in patients with type 2 diabetes
Liraglutide achieves 5.8% reduction in BMI for children aged 6-12
FINE-HEART: Finerenone demonstrates benefits in patients with T2D
Dapagliflozin enhances kidney function and reduces albuminuria in low-renal-risk T2D patients
FLOW-trial: Semaglutide improves kidney and cardiovascular outcomes in type 2 diabetes and chronic kidney disease
Early phase data show albuminuria improvement with avenciguat
Rilparencel leads to kidney function stabilisation in chronic kidney disease and type 2 diabetes
SGLT2 inhibition: A possible mode-of-action for inflammatory skin diseases?
Pemafibrate reduces microvascular complications of PAD and T2D
Interview: Medicare’s first drug price negotiations: concerning?
Efficacy of bardoxolone methyl for DKD, without increased cardiac risk
Heart failure: the 2023 update
Cardiovascular disease and diabetes: new guidelines
High risk of death for individuals with C282Y/C282Y hereditary haemochromatosis and diabetes
Spinal cord stimulation eases painful diabetic neuropathy
Multifaceted strategy improves prescription of therapies for diabetes and ASCVD
Digitally delivered cognitive behavioural therapy successful in type 2 diabetes
Pemafibrate fails to reduce cardiovascular events in diabetes but may benefit the liver
Selonsertib poses risk of AKI in patients with DKD
Diabetes not related to abnormal biomarkers of Alzheimer’s disease
FIDELITY: Cardiorenal benefits of finerenone, regardless of LVH status
Sotagliflozin SCORED MACE benefit
Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes
High treatment success with ixekizumab in patients with psoriasis and diabetes
CHIEF-HF: Canagliflozin improves health status in heart failure
Therapeutic approaches in heart failure with diabetes
VOYAGER PAD: Fragile or diabetic patients also benefit from rivaroxaban
Antagonising the mineralocorticoid receptor beneficial for patients with diabetes and CKD
2021 ESC Guidelines on Heart Failure
2021 ESC Guidelines on Cardiovascular Disease Prevention
Novel mineralocorticoid receptor antagonist effective irrespective of HF history
Empagliflozin linked to lower cardiovascular risk and renal events in real-world study
Efficacy of dapagliflozin and empagliflozin not influenced by diabetes status
Biomarker panel predicts SGLT2 inhibitor response
JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA
Finerenone reduces the risk of AF onset in patients with CKD and diabetes
Obesity: A risk factor for new-onset asthma and worse asthma control
No increased risk of (severe) COVID-19 among IBD patients
10 kHz spinal cord stimulation for painful diabetic neuropathy
Finerenone lowers CV events in diabetic CKD patients
Dapagliflozin reduces renal risk independent of CV disease status
“Strongly consider an SGLT2-inhibitor in most T2DM patients”
2020 Sports Cardiology and Exercise in Cardiovascular Patients Guidelines
SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients
DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes
Antisense ANGPTL3 lowers triglycerides
SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations
The Yale COVID-19 Cardiovascular Registry
TWILIGHT sub-study: same outcomes for diabetes patients
DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status
Phase 3 BETonMACE trial did not meet its primary endpoint
New guidelines on the prevention of cardiovascular conditions
DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups
Penile prosthesis implantation
Embolism/thrombosis
Full-dose or reduced-dose DOACs in high-risk VTE on extended therapy?
Novel risk assessment model acts on increasing hospital-acquired venous thromboembolism rates among children
Head-to-head: Surgical embolectomy versus ultrasound-assisted thrombolysis in high-risk pulmonary embolism
NOAH-AFNET 6: Does the duration of AHRE influence response to edoxaban?
ARTESIA: How useful is anticoagulation in subclinical AF?
Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension
Should we use anticoagulation in AHRE to prevent stroke?
Results of FRAIL-AF trial suggest increased bleeding risk with DOACs
Guidelines for Acute Coronary Syndrome
The optimal duration of anticoagulation therapy in cancer patients with DVT
How to manage arterial thrombosis and thromboembolism in COVID-19?
New analysis assesses the safety of tofacitinib regarding extended MACE
Head-to-head: post-TAVR edoxaban not better than DAPT
Post-pulmonary embolism impairment frequent, follow-up urged after acute PE
Milvexian phase 2 data supports safety and efficacy for VTE prevention after total knee replacement
Support for adapted D-dimer thresholds for ruling out pulmonary embolism
Apixaban tops rivaroxaban for repeat-VTE protection in real-world analysis
Psoriasis tied to small increase in risk of venous thromboembolism, peripheral vascular disease
Recurrent VTE more common than thought with isolated subsegmental pulmonary embolism
Increased risk of cerebral venous thrombosis in COVID-19
Rivaroxaban improves clinical outcomes in discharged COVID-19 patients
COVID-19: Thromboembolic risk reduction with therapeutic heparin dosing
‘Considerable’ bleeding risk with extended anticoagulant therapy after first unexplained VTE
Early switch to DOAC appears safe and effective for intermediate-risk pulmonary embolism
Physiopathology of coagulopathy in haematological malignancies and COVID-19
Haemostatic abnormalities are associated with mortality in COVID-19
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: discovery and diagnosis
Factor XI inhibitor cuts risk of postoperative venous thromboembolism by about 80%
Genotype-based strategy reduces thrombotic events after heart-device implant
Therapeutic anticoagulation not superior to prophylactic anticoagulation in COVID-19
Atorvastatin does not reduce mortality in COVID-19
Many patients on DOACs receive concurrent non-indicated aspirin tied to bleeding risk
PCSK9 inhibition as primary prevention for VTE: Is it LDL or Lp(a)?
Similar outcomes sPESI and HESTIA for pulmonary embolism triage
Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan
DVT screening, early treatment, prevent PE in necrotizing pancreatitis
Physical rehabilitation improves health outcomes after pulmonary embolism
Residual pulmonary obstruction may predict risk of VTE recurrence
Risk of checkpoint inhibitor-associated thromboembolic events important for cancer prognosis
COVID-19 associated with higher VTE rates relative to influenza
Therapeutic anticoagulation not associated with lower mortality rates in COVID-19 ICU patients
COVID-19 not associated with heightened VTE risk after discharge
Higher thrombotic risk in NSCLC patient with ALK rearrangement
Apixaban offers new perspective for cancer patients in need of anticoagulation
Rivaroxaban is safe and effective for paediatric venous thromboembolism
Aspirin plus DOAC is not better than a DOAC alone
Clopidogrel monotherapy after 1-month DAPT may be beneficial in stent patients
Ticagrelor monotherapy safe after dual antiplatelet therapy
Apixaban is safe and effective in real-world setting for treatment of venous thromboembolism
P2Y12 inhibitor monotherapy is a novel antiplatelet strategy after short duration DAPT
Early discharge and home treatment feasible for low-risk pulmonary embolism patients
Epilepsy
Innovations in VNS and DBS for refractory epilepsy
Minimising co-medication optimises cenobamate efficacy in drug-resistant epilepsy
Seizure forecasting and detection with wearable devices are feasible
Encouraging first results of GABAergic interneurons implants for focal epilepsy
Seizure forecasting with non- and minimally-invasive devices
Real-world efficacy of cenobamate in focal-onset seizures
Possible new biomarker for early neuronal death in mesial temporal lobe epilepsy
“Women with epilepsy should be encouraged to breastfeed”
Laser interstitial thermal therapy for refractory epilepsy
Minimally invasive device to detect focal seizure activity
Long-term effectiveness of ANT-DBS in epilepsy confirmed
Good safety and efficacy of cenobamate for focal seizures
Prenatal valproate exposure increases risk of adverse neurodevelopmental outcome
‘Mozart effect’ in epilepsy: why Mozart tops Haydn
Extraordinary transformation of epilepsy care in Ontario
No neurodevelopmental effects of foetal antiseizure medication
Durable seizure frequency reduction with cenobamate
COVID-19 could cause novel seizures in patients without epilepsy
Soticlestat in children with Dravet and Lennox-Gastaut
Listening to Mozart has a beneficial effect on epilepsy
Avoidable epilepsy-related mortality remains high
How genetic testing can contribute to epilepsy management
Cenobamate effective in focal epilepsy
Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome
Prevalence of autoantibodies in epilepsy almost 10%
Neuroinflammatory pathways as biomarkers and treatment targets
Panel of inflammation-associated microRNAs as epilepsy biomarker
Long-term effect of recurrent febrile seizures
Cannabidiol effective in children with Dravet syndrome
Gastroesophageal Cancer
Pre-operative chemoradiation does not improve survival in resectable gastric cancer
Final results of the IKF-AIO-Moonlight trial
OS benefit in ARMANI, but is it worth it?
SPOTLIGHT on new targets in immunotherapy: claudin 18.2
Encouraging efficacy of anti-claudin 18.2 ADC in G/GEJ cancer
New analyses validate TAP and CPS scores for PD-L1 expression
KEYNOTE-585: negative trial, but long-term benefit in PD-L1-high/MSI subgroups?
FLOT outperforms CROSS in resectable oesophageal cancer
Adding docetaxel to standard-of-care does not improve outcomes in gastric cancer
Thoracoscopic oesophagectomy non-inferior to open surgery in thoracic oesophageal cancer
KEYNOTE-590: 5-Year outcomes confirm benefit of pembrolizumab in oesophageal cancer
New standard-of-care for locally advanced oesophageal squamous cell carcinoma?
MATTERHORN: FLOT plus durvalumab leads to high pCR rate in gastric cancer
SKYSCRAPER-08: Adding tiragolumab to oesophageal cancer regimen improves outcomes
CheckMate 648: More quality time for patients with oesophageal cancer on nivolumab
CheckMate 649: Nivolumab plus chemotherapy continues to deliver efficacy benefit in gastric cancer
Modified FLOT regime outperforms FOLFOX in advanced/metastatic gastric/gastroesophageal junction adenocarcinoma
Epinephrine boosts efficiency in gastric ESD
AI detects gastric cancer with high accuracy in common blood tests
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer
Regorafenib offers survival benefit for patients with pre-treated gastric cancer
Radiotherapy or not in locally advanced oesophageal or junctional cancer?
Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial
S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?
LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer
3-year follow-up data confirms benefits of nivolumab plus chemotherapy
Long-term results for nivolumab plus chemotherapy and nivolumab plus ipilimumab in oesophageal cancer
Promising phase 2 results for HER-Vaxx in gastric cancer
Chemo-immunotherapy in gastric cancer is more effective when administered in parallel
Substantial increase of oesophageal cancer prevalence in the middle-aged
EMR versus ESD in oesophageal cancer
Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer
AK104 plus chemotherapy promising first-line option for gastric cancer
DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer
The emerging role of AI in gastroesophageal cancer
DCF outperforms standard-of-care for locally advanced oesophageal cancer
Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome
Updates on pembrolizumab for oesophageal and gastric cancer
Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer
HIPEC in gastric cancer with peritoneal metastases
ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer
ESMO 2021 Highlights Podcast
Benefit of both I-O/chemo combo and I-O/I-O combo over chemotherapy alone in oesophageal squamous cell cancer
Benefit of I-O/chemo combo over chemotherapy alone in advanced GC/GEJC/EAC
Perioperative chemotherapy and neoadjuvant multimodality therapy appear equally effective
Bemarituzumab response for gastric/GEJ cancers correlates with FGFR2b levels
Gut microbiome DELIVERs nivolumab forecast in gastric cancer
OS benefit for trifluridine/tipiracil in advanced gastric cancer from third-line onward
Neoadjuvant chemotherapy does not increase perioperative complications in thoracic oesophageal cancer
Adjuvant nivolumab: good quality-of-life
Adding docetaxel to adjuvant S-1 reduces gastric cancer relapse
Duloxetine ameliorates oxaliplatin-induced peripheral neuropathy
Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?
Nivolumab improves OS in advanced oesophageal cancer
Immunonutrition during neoadjuvant oesophagogastric cancer therapy: no benefit
FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis
KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer
Neoadjuvant chemotherapy as a potential treatment option in colon cancer
Maintenance olaparib improved PFS in patients with BRCA+ pancreatic cancer
GI Cancer
OS benefit in ARMANI, but is it worth it?
SPOTLIGHT on new targets in immunotherapy: claudin 18.2
AI facilitates early detection of hepatocellular carcinoma
Encouraging efficacy of anti-claudin 18.2 ADC in G/GEJ cancer
Durvalumab plus chemotherapy enhances 3-year survival in advanced biliary tract cancer
New analyses validate TAP and CPS scores for PD-L1 expression
KEYNOTE-585: negative trial, but long-term benefit in PD-L1-high/MSI subgroups?
MINOTAUR: Promising phase 1 data for lunresertib plus FOLFIRI
No survival benefit of tumour debulking for patients with multi-organ metastatic CRC
Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC
Neoadjuvant checkpoint blockade in MSI-H/dMMR CRC
CodeBreaK 300: Promising survival trends in KRAS G12C-mutated mCRC
FLOT outperforms CROSS in resectable oesophageal cancer
Nivolumab/ipilimumab combination outperforms TKIs in unresectable HCC
No advantage of neoadjuvant radiochemotherapy over neoadjuvant chemotherapy in borderline resectable pancreatic cancer
Interview: The winding road to curing metastatic colorectal cancer
Adding docetaxel to standard-of-care does not improve outcomes in gastric cancer
Thoracoscopic oesophagectomy non-inferior to open surgery in thoracic oesophageal cancer
KEYNOTE-590: 5-Year outcomes confirm benefit of pembrolizumab in oesophageal cancer
New standard-of-care for locally advanced oesophageal squamous cell carcinoma?
MATTERHORN: FLOT plus durvalumab leads to high pCR rate in gastric cancer
SKYSCRAPER-08: Adding tiragolumab to oesophageal cancer regimen improves outcomes
CheckMate 648: More quality time for patients with oesophageal cancer on nivolumab
Promising efficacy data for next-gen FGFR inhibitor tinengotinib in CCA
NETTER-2: Practice-changing results for 177Lu-DOTATATE in GEP-NETs
EMERALD-1: TACE plus immunotherapy meets primary endpoint in unresectable HCC
Can adjuvant radiotherapy improve outcomes in resected HCC with narrow margin?
Encouraging preliminary data for glecirasib in pancreatic ductal adenocarcinoma
ALPACA: Promising results for dose de-escalated regimen of gemcitabine/nab-paclitaxel in metastatic PDAC
CheckMate 8HW: Excellent results for nivolumab plus ipilimumab in MSI-H/dMMR mCRC
Can ctDNA-directed therapy improve outcomes in low-risk colon cancer?
Clinical biomarkers may guide therapy selection in RAS wildtype mCRC
Laparoscopic or open surgery in low rectal cancer?
Investigational agent DKN-01 promising for advanced MSS CRC
Two potential new first-line standards of care in metastatic urothelial cancer
Perioperative durvalumab/FLOT improves pCR in gastric cancer
Active surveillance after neoadjuvant chemoradiotherapy in oesophageal cancer
FOLFIRINOX equals gemcitabine-based chemoradiotherapy in neoadjuvant setting for pancreatic cancer
Modified FLOT regime outperforms FOLFOX in advanced/metastatic gastric/gastroesophageal junction adenocarcinoma
How to deal with at-risk patients above the CRC screening age limit?
European CRC screening needs to be revised
Epinephrine boosts efficiency in gastric ESD
7-year outcomes of PRODIGE 23 trial
Neoadjuvant chemotherapy may be viable option in locally advanced colon cancer
De-escalation of neoadjuvant treatment of locally advanced rectal cancer is non-inferior
No improved OS in pancreatic cancer after neoadjuvant mFOLFIRINOX
AI detects gastric cancer with high accuracy in common blood tests
Colorectal cancer: Aspirin and NSAIDs could reduce the risk of early-onset adenomas
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
First-line NALIRIFOX superior to standard treatment in mPDAC
Novel approach delivers quality-of-life benefits for patients with pancreatic cancer
Palliative radiation therapy improves hepatic pain in HCC and liver metastasis
Improved survival following postoperative sorafenib plus TACE in HCC
Quality-of-life benefits for tislelizumab in uHCC
Stereotactic body radiation therapy beneficial for patients with locally advanced HCC
SWOG 1815, first-ever phase 3 trial in BTC, fails
IMbrave 151 missed primary endpoint in advanced BTC
Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC
Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC
Mutation-based selection to identify patients suitable for panitumumab treatment
Fucoidan associated with quality-of-life benefits in patients with rectal cancer receiving CCRT
ctDNA appears useful in monitoring patients with anal cancer undergoing CRT
SUNLIGHT trial meets primary endpoint in refractory metastatic CRC
Does cell-free DNA influence MRD testing in post-operative colon cancer?
OPERA: surgery may be avoided with adequate therapy in rectal cancer
Can we improve total neoadjuvant therapy for rectal cancer?
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer
Regorafenib offers survival benefit for patients with pre-treated gastric cancer
Radiotherapy or not in locally advanced oesophageal or junctional cancer?
Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial
S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?
LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer
3-year follow-up data confirms benefits of nivolumab plus chemotherapy
Long-term results for nivolumab plus chemotherapy and nivolumab plus ipilimumab in oesophageal cancer
Promising phase 2 results for HER-Vaxx in gastric cancer
Novel regimen may avoid TME surgery in rectal cancer
Palliative radiation therapy improved hepatic pain in HCC and liver metastasis
Immunotherapy response may be modulated by microbiome
Computer-aided colonoscopies improved adenoma detection rates
Benefit of colon cancer screening with colonoscopy lower than anticipated
Screening-detected colorectal cancers may have superior surgical outcomes
Detection of Europe´s deadliest cancer: much room for improvement
Addition of pembrolizumab to lenvatinib does not improve OS in advanced HCC
New, highly selective inhibitor of FGFR2 driver alterations and resistance mutations
Chemo-immunotherapy in gastric cancer is more effective when administered in parallel
High pathological responses to neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer
Fruquintinib: a potential new treatment for patients with refractory mCRC
Second-line avelumab is effective in patients with MSI-H/dMMR mCRC
Trastuzumab-deruxtecan Potential Second-line Therapy Option in HER2-Positive Gastric Cancer
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer
Spectacular results for dostarlimab in mismatch repair deficient rectal cancer
Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases
To resect or not to resect primary tumours in stage IV colon cancer?
Novel treatment option for KRAS wildtype pancreatic cancer
Substantial increase of oesophageal cancer prevalence in the middle-aged
Cancer detection likely similar for one-time colonoscopy or two fecal immunochemical tests
Metastasis rate high after endoscopic resection of high-risk T1a esophageal cancers
Cumulative exposure to tacrolimus tied to post liver transplant cancer risk
Sintilimab plus FOLFIRINOX may provide benefits in metastatic pancreatic cancer
TRYbeCA-1: Eryaspase + chemotherapy does not meet primary endpoint in pancreatic cancer
Persisting disparities in pancreatic cancer care
ctDNA promising biomarker for recurrence of pancreatic cancer
Head-to-head: Etoposide and irinotecan equally effective in neuroendocrine carcinoma
EMR versus ESD in oesophageal cancer
Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer
AK104 plus chemotherapy promising first-line option for gastric cancer
DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer
The emerging role of AI in gastroesophageal cancer
DCF outperforms standard-of-care for locally advanced oesophageal cancer
Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome
Updates on pembrolizumab for oesophageal and gastric cancer
NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC
Dostarlimab may offer an alternative for dMMR rectal cancer
DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC
Key updates in colorectal cancer screening
Impact of COVID-19 on screening for colorectal cancer
Nivolumab plus standard-of-care does not meet primary endpoint for mCRC
No benefit of additional oxaliplatin in elderly patients with mCRC
Prognostic impact of early oxaliplatin discontinuation in colon cancer unravelled
Long-course chemoradiation versus short-course radiotherapy in rectal cancer
Adjuvant S-1 therapy superior to observation in resected biliary tract cancer
Analysis of metastasectomy in CRC reveals benefits and disparities
Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma
EPOCH trial: Subgroup analyses and additional endpoints for TARE plus chemo
TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer
HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC
LAUNCH: TACE plus lenvatinib efficacious in advanced HCC
Modest activity of atezolizumab plus bevacizumab in Child-Pugh B HCC
p53 mRNA nanotherapy plus anti-PD-1 therapy reverse immunosuppression in a liver cancer model
Sponge-on-a-string device helps detect, monitor early esophageal neoplasia
Early-onset colorectal cancer in young patients is often advanced at diagnosis
BRCA1/2 pathogenic variants linked to prostate, pancreatic and stomach cancers
No benefit to adding trastuzumab to neoadjuvant chemoradiation for HER2 esophageal cancer
Neoadjuvant cemiplimab promising for resectable liver cancer
Overweight, obesity in early adulthood tied to higher risk of early-onset colorectal cancer
Immune checkpoint inhibitors likely best standard therapies for unresectable liver cancer
CRISPR/Cas9 gene editing boosts effectiveness of sonodynamic therapy for liver cancer in mice
Pre-op chemosensitivity tied to post-op survival in patients with gastric tumors
Lowering of CRC-screening age likely to affect colonoscopy demand, case mix, adenoma detection
Belzutifan shows benefit in two conditions that spark tumor growth
Diet that promotes sulfur-metabolizing bacteria tied to colorectal cancer risk
A single flexible sigmoidoscopy screening tied to long-term protection against colorectal cancer
Neoadjuvant chemotherapy potential alternative to neoadjuvant chemoradiotherapy in LARC
Immune chemo-sensitisation looks promising in microsatellite-stable mCRC
Adagrasib shows promising clinical activity in heavily pretreated KRAS-mutated CRC
Automated detection of microsatellite status on unstained samples in early colon cancer
Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer
HIPEC in gastric cancer with peritoneal metastases
ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer
External-beam radiation underused in people with liver cancer awaiting transplant
More adults embraced at-home colorectal-cancer screening during pandemic
Add-on ramucirumab increases PFS, not overall survival, in East Asians with advanced gastric cancer
Adenomas detected per colonoscopy a valid quality measure tied to lower post-colonoscopy CRC
Rising rates of esophageal cancer in young adults, lifestyle may be to blame
Relatives of patients with colorectal carcinoma in situ at higher risk for colorectal cancer
ESMO 2021 Highlights Podcast
Antibiotics tied to increased risk of colorectal cancer
Combined chemoembolization and ablation effective for early-stage hepatocellular carcinoma
Mirati drug combination shrinks tumors in 39% of colon cancer patients in study
New guidelines provide framework for safe liver transplantation for non-resectable colorectal liver metastases
Screening and treating H. pylori in those at high risk for gastric cancer appears cost-effective
More-aggressive therapy not warranted for early-onset colorectal cancer
Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer
Panitumumab added to 5-FU/LV effective as maintenance therapy in patients with mCRC
Trastuzumab-deruxtecan showed promising activity in patients with HER2-expressing mCRC
Benefit of both I-O/chemo combo and I-O/I-O combo over chemotherapy alone in oesophageal squamous cell cancer
Benefit of I-O/chemo combo over chemotherapy alone in advanced GC/GEJC/EAC
AI improves detection of gastric neoplasms during routine endoscopies
Perioperative chemotherapy and neoadjuvant multimodality therapy appear equally effective
Pertuzumab plus trastuzumab promising in HER2-positive biliary-tract cancers
Perioperative SOX protocol bests adjuvant CapOx in locally advanced gastric cancer
Study supports chemopreventive effect of statins on liver cancer in NASH cirrhosis
Donafenib yields survival advantage over sorafenib in Chinese patients with advanced liver cancer
Increased risk of rectal cancer after colectomy in IBD
Risk of colorectal cancer is detected by low-pass whole genome sequencing
Apatinib boosts survival in Chinese patients with advanced liver cancer
Patients with advanced esophageal cancer can skip chemo with upfront dual immunotherapy combo
PARP inhibitor rucaparib helps shrink pancreatic tumors with mutations
Stool-based tests boosted declining screening rates for colorectal cancer during pandemic
Adding aprepitant to other antiemetics further prevents chemo-induced nausea and vomiting
HER2 results in gastric cancer often differ between labs with implications for treatment
Chemoprevention with low-dose aspirin promising in familial adenomatous polyposis
Surgery after chemo can improve survival in stage 2 pancreatic cancer
Nivolumab doubles disease-free survival when residual esophageal cancer lurks
Hypofractionated ablative radiation tied to improved survival in pancreatic cancer
Liquid biopsy after hepatectomy promising aid in metastatic colorectal cancer
First-line pembrolizumab shows superior PFS in MSI-H/dMMR mCRC
Short-course radiotherapy with delayed surgery better for elderly rectal cancer patients
Bemarituzumab response for gastric/GEJ cancers correlates with FGFR2b levels
Circulating tumour DNA predicts recurrence in colorectal cancer
Gut microbiome DELIVERs nivolumab forecast in gastric cancer
Ivosidenib in second-line improves OS in IDH1-mutant cholangiocarcinoma
Neoadjuvant pembrolizumab in locally-advanced rectal cancer: primary results
OS benefit for trifluridine/tipiracil in advanced gastric cancer from third-line onward
Prognostic value of tumour deposits in stage 3 colon cancer patients
Final phase 2 results of second-line infigratinib for advanced cholangiocarcinoma
Neoadjuvant chemotherapy does not increase perioperative complications in thoracic oesophageal cancer
Ipilimumab/nivolumab plus panitumumab in patients with microsatellite-stable mCRC
Adjuvant nivolumab: good quality-of-life
Preliminary surgery salvage data after watch & wait policy from OPERA trial
Landmark OS for HCC, updated IMbrave150 data
Adding docetaxel to adjuvant S-1 reduces gastric cancer relapse
Second-line pembrolizumab after progression on sorafenib benefits OS/PFS in advanced HCC
Predicting resistance to first-line FOLFOX plus bevacizumab in mCRC using circulating markers
Phase 2 study supports first-line pembrolizumab in advanced HCC
Final OS analyses comparing trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line unresectable mCRC patients noneligible for intensive therapy
Yttrium-90 (Y-90) glass microspheres for HCC
Maintenance treatment with cetuximab versus observation in RAS wildtype mCRC
Duloxetine ameliorates oxaliplatin-induced peripheral neuropathy
Sorafenib extends PFS, but not OS, for HCC transcatheter arterial chemoembolisation
Zanidatamab provides ORR in HER2+ biliary tract cancer
Borderline resectable pancreatic cancer: phase 2 results
No survival benefit for olaparib in BRCA-mutated metastatic pancreatic cancer
Metastatic pancreatic adenocarcinoma: second-line naI-IRI plus 5-FU/LV
COVID-19 impact on gastrointestinal cancer care
Treatment delay for cholangiocarcinoma adjuvant therapy does not affect OS
No benefit of adding axitinib to ocreotide acetate in non-pancreatic neuroendocrine tumours
Phase 2 abemaciclib trial in patients with advanced NETs
Neoadjuvant chemo for intrahepatic cholangiocarcinoma may prolong life
No survival benefit to primary resection before chemo in metastatic colorectal cancer
Drug combo yields longest-ever survival in advanced liver cancer
Radiotherapy for rectal cancer linked to risk for later malignant gynecological neoplasms
Organ preservation possible in early-stage rectal cancer
Radiotherapy then chemotherapy before surgery may be best in rectal cancer
Carcinoid tumors increasing in young adults at a faster clip than adencarcinomas
Rechallenge of RAS/BRAF wildtype CRC with avelumab plus cetuximab
Adjuvant chemotherapy less effective in elderly CRC patients
Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?
No survival differences with open or laparoscopic surgery for liver metastases
Risk-adapted starting ages proposed for colorectal cancer screening in diabetics
Pembrolizumab prolongs overall survival in some with advanced esophageal cancer
Adenoma detection rate improves over time
Post-colonoscopy colorectal cancers in IBD patients
Colorectal cancer more likely after first acute diverticulitis
Linked color imaging bests conventional imaging for upper GI cancer detection
Invasive features, positive margins tied to worse outcome of precancerous pancreas lesions
Surufatinib improves progression-free survival in advanced pancreatic neuroendocrine tumors
MR-Linac-delivered adaptive radiation therapy promising in pancreatic cancer
Vascular invasion, tumor deposits more prognostic than TNM for rectal cancer
HER2-expressing metastatic colorectal cancer: trastuzumab deruxtecan
Pembrolizumab as first-line in MSI-H mCRC
REGOMUNE: a phase 2 study combining regorafenib and avelumab
Cardiotoxicity: consider switching to S-1
Perioperative chemotherapy for resectable pancreatic ductal adenocarcinoma
Real-world data of sequential sorafenib followed by regorafenib in unresectable HCC
Eflornithine-sulindac combo may not offer extra benefit for familial adenomatous polyposis
Role of immune cells in intestinal fibrosis
Increased risk of small bowel cancer in IBD
Increased incidence of colorectal cancer and death in CD
Risk of rectal, anal cancer increased in perianal CD
Glyco-fingerprint as risk factor of UC-associated cancer
Mixed data: AMG 510 in tumours with KRASG12C
Preoperative chemotherapy for colon cancer
Nivolumab improves OS in advanced oesophageal cancer
Liquid biopsy identifies relapse in patients with colorectal cancer after surgery
In hepatocellular carcinoma, CheckMate 459 misses OS endpoint, but some interesting trends emerge
Heavily pre-treated GIST: ripretinib improves PFS
FGFR2+ cholangiocarcinoma: pemigatinib active as second-line treatment
IDH1+ cholangiocarcinoma: phase 3 results show improved PFS
Advanced colorectal cancer and BRAF mutations: triplet combination improves survival
Early stages of gastric metaplasia: molecular profiling
Metal stents are better than plastic for endoscopic biliary drainage
Ramosetron relieves low anterior resection syndrome
Global burden of digestive diseases reveals alarming trends
Immunonutrition during neoadjuvant oesophagogastric cancer therapy: no benefit
IBD prevalence 3 times higher than estimated and expected to rise
FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis
KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer
Neoadjuvant chemotherapy as a potential treatment option in colon cancer
Laparascopic surgery; less morbidity, same survival benefits as open surgery in colorectal cancer with liver metastases
Maintenance olaparib improved PFS in patients with BRCA+ pancreatic cancer
First-in-human study shows IL1RAP-targeting drug safe in solid tumours
Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD
Shallow whole-genome sequencing predicts future cancer risk of LGD in UC
Significantly increased risk of CRC and/or HGD after appendectomy in UC
Genitourinary Cancer
Immune-enhancing nutrition does not affect complication rate of radical cystectomy
Biomarkers for treatment of renal cell carcinoma
ctDNA changes as biomarker for pembrolizumab response in advanced urothelial carcinoma
Highest efficacy of nivolumab/chemotherapy in lymph-node-only metastatic urothelial carcinoma
Metformin does not prevent progression of low-risk prostate cancer
Baseline ctDNA has both prognostic and predictive value in mCRPC
Oxybutynin significantly decreases frequency and severity of hot flashes in men on ADT
LuPSMA and enzalutamide: a promising combination
No benefit of erdafitinib over pembrolizumab in urothelial cancer second-line therapy
Combining PARP inhibition and androgen receptor-signalling inhibition improves radiographic progression-free survival in HRR-deficient mCRPC
Erdafitinib outperforms chemotherapy in FGFR-altered advanced urothelial cancer
Probiotic CBM588 seems to improve clinical effect cabozantinib/nivolumab in mRCC
Exploratory analysis of IMvigor130 trial finds no OS benefit from atezolizumab in subgroups
Immune checkpoint inhibition improves PFS in non-BRCA-mutated ovarian cancer
The road to improving doctor-patient interactions in kidney cancer
OS benefit for advanced ovarian cancer patients treated with maintenance olaparib
Maintenance tegafur-uracil does not improve survival in locally advanced cervical cancer
Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy
Triple therapy improves progression-free survival in patients with advanced RCC versus dual therapy
Adjuvant atezolizumab does not improve outcomes for patients with RCC and increased risk of recurrence
Overall survival benefit of abiraterone in mHSPC is maintained for 7 years
Limited benefit of adding long-term ADT to post-operative radiotherapy in prostate cancer
Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer
Exploratory treatment options fail in ccRCC
Adjuvant everolimus did not benefit high-risk renal cell carcinoma
Cabozantinib fails as first-line maintenance therapy in urothelial cancer
177Lu-PSMA-617 is a valid treatment option for PSMA-positive mCRPC
Enzalutamide performs well in metastatic hormone-sensitive prostate cancer
Does systematic biopsy add value to the detection rate of prostate cancer?
PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer
Prostate cancer treatments reduce quality of life
PROpel: Good results for abiraterone plus olaparib in mCRPC
Neoadjuvant hormonal therapy promising in high-risk prostate cancer
Darolutamide performs well across subgroups in mHSPC
Shorter hospital stay with robotic surgery versus open surgery in bladder cancer
Improved risk stratification for high-risk NMIBC
Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma
New prognostication in N3 penile cancer
KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC
Fewer complications with robotic surgery in renal cancer
Support for risk-adapted androgen deprivation plus high-dose radiotherapy in prostate cancer
First-line treatment with olaparib significantly improves PFS in mCRPC
First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC
Darolutamide improves OS in mHSPC
Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide
Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence
PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel
Artificial intelligence improves prediction of long-term outcomes
Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer
Addition of abiraterone to ADT/docetaxel does not increase bone loss
Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity
No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma
Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma
Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC
Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma
Maintenance niraparib fails to improve PFS in advanced urothelial cancer
First-line avelumab shows clinical activity in advanced urothelial carcinoma
Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma
Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma
Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer
Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin
High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib
DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up
Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC
Combined nivolumab/axitinib treatment elicits good response in metastatic RCC
Folliculin mutations not associated with sporadic chromophobe RCC
Differential patterns of molecular alterations among sites of metastasis in RCC
Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC
HPV-positive and HPV-negative penile squamous cell carcinoma are molecularly distinct tumours
Atezolizumab does not improve survival in advanced penile cancer
Biomarkers to distinguish necrosis from teratoma before pcRPLND in testicular cancer
No survival benefit found in routine screening MRI for spinal cord compression in prostate cancer
Changes in genitourinary cancer management during the pandemic: findings and implications
Large phase 3 trial tests novel combinations for metastatic RCC
Positive phase-3 data for PARP inhibitor niraparib in ovarian cancer
Can nitrogen-based bisphosphonates protect against ovarian cancer?
Breast, cervical screening suboptimal in transgender individuals
Bayer’s Nubeqa drug significantly prolongs survival in prostate cancer trial
Pregnancy outcomes improving after treatment for high-grade cervical neoplasia
Brachytherapy boost may allow for shorter androgen deprivation therapy with EBRT
BRCA1/2 pathogenic variants linked to prostate, pancreatic and stomach cancers
Blacks in clinical trials respond better than whites to radiation for localized prostate cancer
Drop in PSA tied to better outcomes of apalutamide therapy in prostate cancer
Upfront immunotherapy combo means less time on treatment in advanced kidney cancer
PSA testing rose after revised USPSTF guideline, even among those deemed ineligible
Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment
TKI drug-free interval strategy not detrimental to conventional continuation strategy in RCC
Modified ipilimumab schedule reduces risk of grade 3/4 adverse events
Optimal neoadjuvant dose ipilimumab/nivolumab in stage III urothelial cancer
Better survival with neoadjuvant dose-dense MVAC regimen in MIBC
PARP inhibitor rechallenge improves PFS in ovarian cancer
Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer
Pembrolizumab has durable effect in previously treated MSI-H/dMMR advanced endometrial cancer
HRR mutational status is prognostic and predictive biomarker olaparib activity
Genetic test can help pinpoint best treatment for men with high-risk prostate cancer
Shortened course of radiotherapy the new standard following prostatectomy
Androgen-annihilation therapy prolongs progression-free survival in metastatic prostate cancer
Online risk tool facilitates decision making in early, non-metastatic prostate cancer
PSMA PET imaging pinpoints most pelvic nodal metastases in high-risk prostate cancer
Pembrolizumab hikes survival by 36% at 24-month mark in cervical cancer study
Adding ADT to radiation works better than upping radiation dose for some prostate cancers
Best of EAU: Highlights on bladder cancer
ctDNA can guide adjuvant immunotherapy in muscle-invasive bladder cancer
Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma
Circulating tumour cells could aid in the decision to give neoadjuvant chemotherapy
Best of EAU: New advances in testicular and penile cancer
Recommendations for the management of indeterminate small testis masses
Residual tumour resection in case of elevated markers
Best of EAU: Updates on imaging and treatment of prostate cancer
Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC
177Lu-PSMA-617: A new class of effective therapy
In women with breast or ovarian cancer, pathogenic gene variants linked with increased survival
Novel blood test plus MRI-targeted biopsy shows promise for prostate-cancer screening
Adjuvant chemotherapy does not improve outcome in patients with locally advanced cervical cancer
VISION trial shows improved survival with 177Lu-PSMA-617 in mCRPC
Novel drug combination for recurrent ovarian cancer
Abiraterone added to ADT + docetaxel nearly doubles survival in de novo mCSPC
Dual HER2-blockade shows anti-tumour activity in patients with uterine cancer
Promising efficacy and safety of feladilimab in recurrent/metastatic urothelial carcinoma
The EFFORT needed to overcome PARP resistance in ovarian cancer
Androgen blockers likely boost survival in older men with non-metastatic CR prostate cancer
Urinary thromboxane B2 may be marker of aggressive prostate cancer in Black men
Combination therapy shows promise in oligorecurrent pelvic-node relapses of prostate cancer
Common advanced prostate cancer treatments not tied to significant cognitive decline
Nicotine by-product in urine a potential biomarker of bladder cancer recurrence
MRI screening for prostate cancer prevents many unnecessary biopsies
Guideline-concordant multimodality care tied to fewer deaths in high-risk prostate cancer
Adding pembrolizumab to chemo provides little or no benefit in urothelial cancer
Adding pembrolizumab to chemo provides little or no benefit in urothelial cancer
Radical prostatectomy shifting to higher-risk cases in era of active surveillance
Adjuvant likely bests salvage radiation in high-risk prostate cancer
Genetic analysis shows race-specific tumor alterations tied to racial disparities in prostate cancer
Targeted radiotherapy improves survival in metastatic castration-resistant prostate cancer
Longer-term analysis finds survival benefit of atezolizumab in metastatic bladder cancer
Low diagnostic yield with cystoscopy and CT urography for urinary tract cancers
Patients on hormonal therapies for cancer should be monitored for heart risk – AHA
Loss of MAP3K7 and CHD1 expression drive recurrence, resistance in prostate cancer
Biologic drug nearly doubles overall survival in metastatic triple-negative breast cancer
ASCO Genitourinary Cancers Symposium: New therapy prolongs survival for patients with urothelial carcinoma
ASCO-GU Highlight: Cabozantinib plus nivolumab provides better QoL than sunitinib
Novel genomic alterations in circulating tumor cells tied to castrate-resistant prostate cancer
BRCA1/2 mutations raise risk for endometrial cancer, too
Targeting glutamine could curb castration-resistant prostate cancer
Researchers call for an overhaul of licensing and funding of anti-cancer drugs
Exploring a new strategy for metastatic germ cell tumours
Poorer outcomes in bladder cancer predicted by race/ethnicity and gender
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 3 results
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 2 results
New standard of care recommended for patients with upper tract urothelial cancer
Signature DNA alterations in subtypes of bladder cancer
ACE inhibitors associated with superior responses in bladder cancer
Better allocation of research dollars needed
Better prediction of favourable responses to immune checkpoint inhibitors in mUC
New prediction model for brain metastasis in germ cell tumours
Reduction in radiation exposure is possible in testicular seminoma surveillance
New therapeutic option for early metastatic seminoma
Prognosis of penile cancer associated with HPV status
Lu177 as a promising new therapy for metastatic prostate cancer
Role of prostate cancer genomics is evolving
Apalutamide prolongs progression-free survival in prostate cancer
Dose-intensified radiation therapy fails to provide better outcomes in prostate cancer
Intrinsic tumour biology may be predictive of treatment response in prostate cancer
Final TITAN trial results favour use of apalutamide
No benefit of dose-intensified salvage radiation for prostate-cancer recurrence
Adjuvant nivolumab prolongs disease-free survival in high-risk urothelial carcinoma
Apalutamide added to ADT prolongs life in men with metastatic castration-sensitive prostate cancer
Abundance of plasma cells tied to better outcomes in Blacks with prostate cancer
Uptick in diagnoses of metastatic prostate cancer tied to reduced PSA screening
Liquid biopsies helpful in prostate cancer, but most not ready for routine use
Two cases show fetus can get lung cancer during delivery if mother has cervical cancer
First-line immune-combination therapies in mUC
Palbociclib effective in ER-positive endometrial cancer
Platinum-based therapy could be helpful in some with advanced prostate cancer
Women with cervical cancer at increased risk of injury during diagnostic workup
Rates of bone density testing in men initiating ADT low but rising
Radiation therapy, brachytherapy outcomes similar for localized prostate cancer
HPV vaccination tied to lower risk of invasive cervical cancer
Proton-pump inhibitors may reduce benefits of atezolizumab in urothelial carcinoma
Avelumab shows survival benefit against advanced urothelial cancer
Urothelial cancer: avelumab works as maintenance therapy
ARAMIS final OS and nmCRPC safety outcomes
Final survival results from phase 3 SPARTAN trial
Novel drug for kidney cancers/VHL patients
Primary analysis from IMvigor010, adjuvant atezolizumab in high risk muscle-invasive urothelial carcinoma
First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel
Follow-up confirms apalutamide survival benefits in some men with prostate cancer
Androgen deprivation appears beneficial in unfavorable intermediate-risk PC
Accurate prediction of bladder-cancer response to neoadjuvant chemotherapy remains elusive
Darolutamide lowers risk of death by 31% for some prostate-cancer patients
Ipilimumab prolongs overall survival in metastatic castration-resistant prostate cancer
Maintenance olaparib improves OS in relapsed ovarian cancer with BRCA1/2 mutation
DNA-methylation test shows promise in bladder-cancer detection, monitoring
Infertility and testis cancer risk: causal or association?
Prostatectomy: R-LRPE better than LRPE for continence
PSMA PET-CT staging is 27% more accurate
Docetaxel + hormonal therapy: improved prostate cancer PFS
ARAMIS subgroup analysis: darolutamide benefits across PSADT groups
Large patient-driven survey reveals QoL issues after prostate cancer treatment
Targeting steroid sulphatase in resistant prostate cancer cells
Good tolerance of post-RP radiotherapy ± short-term ADT
Reduced BCG frequency, faster NMIBC recurrence
Nadofaragene firadenovec effective in BCG-unresponsive papillary NMIBC
Understanding MIBC biology for novel treatment options
Ovarian cancer patients benefit from combined maintenance therapy
25% reduction in the risk of death in patients with nmCRPC treated with apalutamide
Combination of PARP inhibition plus chemotherapy in ovarian cancer
Enfortumab vedotin and pembrolizumab in advanced bladder cancer: initial results
PARP inhibition in selected patients slows progression on advanced prostate cancer
PFS extension with immunotherapy + chemotherapy in urothelial cancer
Third-line in mCRPC: CARD trial
Prostate cancer: spare radiotherapy after surgery
PFS benefit with niraparib as first-line maintenance in ovarian cancer
Enzalutamide offers survival advantage over other NSAAs in mHSPC
Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer
Enfortumab vedotin highly active in previously treated advanced urothelial carcinoma
Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer
Largest safety study of its kind with atezolizumab in metastatic bladder cancer
HPV and penile cancer
Prostate cancer active surveillance: Better patient risk stratification and use of imaging
Consensus treatment pathway for patients with limited pelvic lymph node involvement in otherwise localised bladder cancer
The role of pelvic lymph node dissection in prostate cancer: Extended vs standard
When to use imaging and imaging-guided therapies
FGFR3 gene mutation: Favourable prognostic impact in bladder cancer
Bladder cancer in young patients
Radioguided surgery is the future?
Spanish study directly links surgical volume with mortality in bladder cancer patients undergoing cystectomy
Cytoreductive radical prostatectomy: LoMP trial results
Updated interim results of phase 2 trial of pembrolizumab for high-risk NMIBC unresponsive to BCG
Prostate cancer: What to expect the next 12 months
Robot-assisted radical cystectomy or open radical cystectomy?
Gynaecological Cancer
Increased OS with pembrolizumab in newly diagnosed, high-risk, locally advanced cervical cancer
Doublet maintenance therapy does not outperform monotherapy in ovarian cancer
Benefit of pembrolizumab in dMMR, newly diagnosed, high-risk endometrial cancer
No OS benefit of niraparib maintenance in high-risk ovarian cancer
Batiraxcept shows promise in high AXL-expressing, platinum-resistant ovarian cancer
No lymphadenectomy for advanced ovarian cancer without suspicious nodes
SIENDO: Efficacy benefit of selinexor in TP53 wildtype endometrial cancer
Novel regimen for HR-positive endometrial cancer on the way?
Addition of atezolizumab to chemotherapy and maintenance PARP inhibitor has no benefit in ovarian cancer
Neoadjuvant immune checkpoint blockade safe and effective in MMRd endometrial cancer
Top 10 medical breakthroughs in 2023
Immune checkpoint inhibition improves PFS in non-BRCA-mutated ovarian cancer
When to screen for anal intraepithelial neoplasia?
OS benefit for advanced ovarian cancer patients treated with maintenance olaparib
Maintenance tegafur-uracil does not improve survival in locally advanced cervical cancer
Primary results of rucaparib in ovarian cancer
Trabectedin not superior to chemotherapy in recurrent epithelial ovarian cancer
Encouraging results of relacorilant in ovarian cancer
How tamoxifen can induce uterine cancer
PARP inhibitor rechallenge improves PFS in ovarian cancer
Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer
Pembrolizumab has durable effect in previously treated MSI-H/dMMR advanced endometrial cancer
HRR mutational status is prognostic and predictive biomarker olaparib activity
Adjuvant chemotherapy does not improve outcome in patients with locally advanced cervical cancer
Novel drug combination for recurrent ovarian cancer
Dual HER2-blockade shows anti-tumour activity in patients with uterine cancer
The EFFORT needed to overcome PARP resistance in ovarian cancer
Palbociclib effective in ER-positive endometrial cancer
Ovarian cancer patients benefit from combined maintenance therapy
Combination of PARP inhibition plus chemotherapy in ovarian cancer
PFS benefit with niraparib as first-line maintenance in ovarian cancer
Haemophilia
Durable responses to gene therapy in haemophilia A
Fitusiran meets primary endpoint in ATLAS-A/B trial
ATLAS-INH: Impressive results of fitusiran for haemophilia with inhibitors
rFVIIIFc establishes rapid tolerisation in haemophilia A with inhibitors
First results from gene therapy trial in haemophilia B
Impact of haemophilia on children and their caregivers
Novel gene therapy leads to normal FIX activity levels in severe haemophilia B
Haemophilia gene therapy: progress and obstacles
Recombinant factor VIII safe and effective in PUPs A-LONG study
Heart Failure
FAIR-HF2: the value of intravenous iron in patients with HF plus iron deficiency
Restricting fluid in HF may not be good practice after all
Will myeloperoxidase inhibition benefit patients with heart failure?
Is intranasal bumetanide a viable diuretic option in congestive HF?
REALIZE-K: MRA treatment optimisation in HFrEF plus hyperkalaemia
SUMMIT: Tirzepatide reduces cardiovascular events in HFpEF plus obesity
FINEARTS-HF: Finerenone improves outcomes in heart failure with preserved ejection fraction
MRAs show varied efficacy in heart failure across ejection fractions
RESHAPE-HF2: Not a “tie-breaker” for TEER in heart failure
Meet the Expert: Dr Abdullahi Mohamed on Iron Deficiency in Patients with HF
Effects of semaglutide on MACE irrespective of HF status
SEQUOIA-HCM: Aficamten demonstrates clinical efficacy in obstructive HCM
ARIES-HM3 trial: Subgroup analysis in patients with prior need for aspirin
Three diuretic regimens compared in the DEA-HF study
Adding a mineralocorticoid receptor modulator in heart failure with CKD
Empagliflozin did not reduce mortality for HF after MI regardless of T2D status
SGLT2 inhibitors decrease atrial fibrillation risk in patients with HFrEF
SGLT2 inhibition: Major and early impact on heart failure hospitalisation risk
Individualised diuretic titration in acute HF without a physician
Intravenous iron deficiency treatment improves exercise capacity in patients with HFpEF
CD34+ stem cells promote reverse cardiac remodelling after acute MI
Sex-specific outcomes and resource utilisation after HF hospitalisation
Application of guideline-directed medical therapy in patients with HFrEF in the Netherlands
PAP-guided management system appears safe in patients with HF
Delivery of CRT guided by non-invasive anatomy assessment
RELIEVE-ing HFrEF with interatrial shunting
Algorithm-based remote patient monitoring was associated with lower mortality in a retrospective cohort study
High mortality and morbidity in suspected de novo HF in outpatient care
Bio-ADM as a marker for congestion in patients hospitalised for acute HF
Hypertonic saline not effective in ambulatory patients with heart failure?
No effect of low-dose carperitide on mortality or hospitalisation in acute HF
Meet the Trialist: Innovating cardiac monitoring with MONITOR-HF
SGLT2 inhibition in heart failure more advantageous for women than men
Interatrial shunt for HF: neutral primary endpoint but potential benefit in HFrEF
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
IMPROVE-HCM: Promising results for ninerafaxstat in non-obstructive HCM
Meet the Trialist: The “Sweet Spot” from RELIEVE-HF
Meet the Trialist: The EMPACT-MI trial findings
Matters of the heart: late-breaking news from the American College of Cardiology
Can a walking intervention improve functional status and quality of life in HFrEF?
Traditional Chinese medicine successful in HFrEF
CRT upgrade benefits patients with HFrEF and an ICD
Catheter ablation saves lives in end-stage HF with AF
Meta-analysis: Does FCM improve clinical outcomes in HF?
HEART-FID: Is intravenous ferric carboxymaltose helpful in HFrEF with iron deficiency?
Heart failure: the 2023 update
Natriuresis-guided diuretic therapy to facilitate decongestion in acute HF
DICTATE-AHF: Early dapagliflozin to manage acute HF
STEP-HFpEF: Semaglutide safe and efficacious in HFpEF plus obesity
Frequent co-existence of atrial fibrillation and obstructive sleep apnoea in stroke patients
Protein-bound uremic toxins predict HF events and death in patients with CKD
VOICE-COVID-II : Alexa successful in SARS-CoV-2 symptoms screening
HF patients with metabolic dysfunction at high risk to develop depressive symptoms
Standardised diuretic protocol significantly increases natriuresis in acute HF
Low concentrations of VEGF-C: a negative prognostic factor
Patisiran benefits maintained over 18 months in patients with transthyretin amyloidosis
Sacubitril/valsartan reduces natriuretic peptides in HF patients with ejection fraction >40%
Clinically relevant reduction in HF hospitalisation due to haemodynamic monitoring
TRACER-HF: Trientine reduced biomarkers up to 8 weeks
Dapagliflozin improves LAVI, LV mass, and concentration of natriuretic peptides after 6 months
NUDGE-FLU: Repeated electronic nudges improve flu vaccination rates in patients with HF
No difference in CV outcomes between PET or CMR and SPECT
Benefits of MitraClip sustained to 5 years in COAPT trial
Transcatheter repair for patients with tricuspid regurgitation
Statins associated with reduced heart dysfunction from anthracyclines
Does adaptive pacing work in patients with HF, LBBB, and intact AV conduction?
ANTWERP score selects HF patients for AF ablation
Torsemide not superior to furosemide after hospitalisation for heart failure
IRONMAN failed primary endpoint but shows potential long-term benefits of iron repletion in HF patients
Up-titration of HF therapies following HF discharge saves lives
Extracorporeal membrane oxygenation not superior to conservative therapy in cardiogenic shock
New analysis assesses the safety of tofacitinib regarding extended MACE
Old dogs, new tricks: Acetazolamide plus loop diuretics improves decongestion
No effect of neprilysin inhibition on cognition
Dapagliflozin DELIVERs for HFmrEF/HFpEF
Pooled analysis of DAPA-HF and DELIVER
Meta-analysis of DELIVER and EMPEROR-Preserved